Healthcare & Life Sciences — March 31, 2026

BECZELTEV Trademark Application for Pharmaceutical Preparations

USPTO received trademark application TM99424865 for the word mark "BECZELTEV" filed October 2, 2025. The application is classified under Class 5 (pharmaceutical preparations) and covers goods for the treatment of cancer, autoimmune and inflammatory diseases, and infectious diseases. This is an Intent-to-Use application, indicating the applicant plans to use the mark in commerce but has not yet done so.

HERLYSTIC trademark application for HER2 cancer treatment

The USPTO received trademark application TM99431686 for HERLYSTIC, filed October 7, 2025, covering pharmaceutical preparations targeting the HER2 protein for cancer treatment. The application is filed as Intent-to-Use, indicating the applicant plans to commercialize the mark in the future. This is an informational notice of a trademark filing in Class 005 (pharmaceuticals).

Independent Gripper for Tissue Repair

The USPTO granted patent US12588908B2 to Abbott Cardiovascular Systems Inc. on March 31, 2026. The patent covers an independent gripper device for tissue approximation and repair during therapeutic procedures, including endovascular, minimally-invasive, and open surgical operations. The invention includes 15 claims and is particularly useful for accessing remote tissue locations through tortuous anatomical pathways.

Healthcare Mirror with Temperature Sensor Patent Grant

USPTO granted patent US12588901B2 to Kohler Co. for a healthcare mirror apparatus featuring an integrated temperature sensor and controller for analyzing physiological data. The patent, filed June 10, 2021 under application number 17343876, contains 17 claims and covers mirror frame, sensor cavity, and temperature monitoring functionality.

Implant devices and fabrication methods for tissue repair

The USPTO granted Patent US12588904B2 to Miach Orthopaedics, Inc. for implant devices and fabrication methods configured to repair tissue. The patent covers devices with distal and proximate ends connectable to tissue parts, a substrate with a longitudinal axis, preformed channels, and preloaded sutures. The patent lists Stephen Wohlert as inventor and classifies under CPC categories including A61B 17/0401, A61L 27/3633, and A61F 2/08.

Suturing Device Patent

USPTO granted patent US12588906B1 to DURASTAT LLC for a suturing device. The device includes an elongate first member with footplate and slot, distal and proximal carriages, a receiver with suture connector capture, and an elastic coupling that compresses upon contacting obstructions. The patent contains 19 claims covering medical suturing technology.

Ultrasonic diagnostic apparatus with machine learning

USPTO granted Patent US12588899B2 to Canon Kabushiki Kaisha for an ultrasonic diagnostic apparatus that uses machine learning models to generate estimated images from reduced transmission/reception ultrasonic scan data. The patent covers technology that trains models on data from varying numbers of ultrasonic transmissions to produce high-quality images from fewer scans.

Knee joint capsular disruption and repair

USPTO granted patent US12588905B2 to Arthrex, Inc. covering methods to repair meniscal extrusion caused by knee capsule detachment. The patent includes 20 claims spanning surgical repair techniques and cadaveric/synthetic training models. Assignee: Arthrex, Inc. Inventors include David Crane, George Paletta, and others.

Shear-Wave Elastography Ultrasound Imaging Patent Grant

USPTO granted Patent US12588898B2 to eight inventors for methods of shear-wave elastography liver imaging using ultrasound. The patent covers receiving segmented ultrasound image data of a liver, automatically identifying regions of interest for elastography, and presenting the data on a display. The patent contains 13 claims and covers CPC classifications A61B 8/469 and A61B 8/485.

Imaging assembly for intraluminal imaging

USPTO granted patent US12588894B2 to Koninklijke Philips N.V. for an intraluminal imaging device featuring a flexible elongate member and imaging assembly with ultrasound transducer elements on a flexible substrate. The patent, filed March 7, 2018, contains 21 claims and is classified under A61B 8/12 and related diagnostic ultrasound categories.

Fat mass derivation device, method, and program

The USPTO granted Patent US12588885B2 to FUJIFILM Corporation on March 31, 2026, covering a fat mass derivation device, method, and program. The technology derives fat mass and visceral fat distributions from dual-energy radiation images. The patent includes 13 claims and is assigned to inventor Tomoyuki Takahashi.

Medical device position sensing components

USPTO granted patent US12588887B2 to Boston Scientific Scimed, Inc. on March 31, 2026. The patent covers a medical device needle with integrated position sensing components for determining the position and orientation of a distal tip during medical procedures. The device includes a handle, sheath, core, and a transmitter or receiver device for a position sensing system.

High-resolution ultrasonography of gingival biomarkers for periodontal diagnosis

The USPTO granted patent US12588888B2 to The Regents of the University of California for a method of periodontal disease diagnosis using B-mode ultrasound imaging. The patent covers identifying specific gingival biomarkers (GM, ABC, CEJ, PDL, GE) to evaluate periodontal disease metrics and guide therapeutic treatment. The patent names Jesse Vincent Jokerst, Colman Arthur Moore, and Casey Chen as inventors.

Fujifilm Ultrasonic Endoscope Patent Grant

The USPTO granted Patent US12588889B2 to FUJIFILM Corporation for an ultrasonic endoscope device featuring a pressing portion on the inner peripheral surface of a base member. The invention addresses light guide fiber positioning with a pressing surface against which a pressed portion of the light guide fiber is pressed. The patent contains 4 claims and was filed by inventor Masaya Inoue.

Acoustic Wave Diagnostic Apparatus and Control Method

USPTO granted patent US12588891B2 to FUJIFILM Corporation covering an acoustic wave diagnostic apparatus with automatic measurement target recognition and algorithmic measurement capabilities. The patent includes 15 claims relating to ultrasound imaging technology for medical diagnostics. Patent expires November 27, 2040 based on original filing date.

Tablet Ultrasound System

USPTO granted patent US12588893B2 to Teratech Corporation on March 31, 2026, covering tablet-based portable medical ultrasound imaging systems with touchscreen controls, multi-chip module engine boards, and real-time 3D imaging capabilities. The patent lists 43 claims and names inventors Alice M. Chiang, William M. Wong, and Noah Berger.

Ultrasound diagnostic apparatus and control method of ultrasound diagnostic apparatus

The USPTO granted Patent US12588896B2 to FUJIFILM Corporation for an ultrasound diagnostic apparatus that detects sampling target regions in breast tissue and displays recommended needle insertion paths on a monitor. The apparatus includes a needle detection unit and passage determination unit to verify tissue sampling accuracy. Invented by Riko Koshino, Application No. 18046869 was filed October 14, 2022.

Flexible Two-Dimensional Ultrasound Phased Array System

The USPTO granted patent US12588895B2 to inventors Kenneth Shepard, Jeffrey Ellosian, and Tiago Costa for a flexible two-dimensional ultrasound phased array system. The invention comprises a flexible substrate with integrated circuits that control ultrasound transducer excitation phases based on substrate shape. This patent covers medical ultrasound imaging applications including diagnostic and surgical guidance.

CMS 1135 Waiver Request - Paperwork Reduction Act Notice

CMS published a notice under the Paperwork Reduction Act announcing a 60-day public comment period on a revision to the existing 1135 Waiver Request information collection (OMB Control No. 0938-1384). The collection supports the Acute Hospital Care at Home (AHCAH) program. Comments are due by June 1, 2026.

Portable radiographic imaging apparatus and radiographic imaging system

USPTO granted patent US12588880B2 to Konica Minolta, Inc. on March 31, 2026. The patent covers a portable radiographic imaging apparatus with a plurality of connectors supporting generic and non-generic communication cables. The patent has 6 claims and is classified under CPC A61B 6/4233, A61B 6/4283, A61B 6/4405, and A61B 6/56.

X-ray detector and radiographic X-ray apparatus

USPTO granted patent US12588878B2 to Sharp Display Technology Corporation for an X-ray detector featuring alternately stacked scintillators and low refractive index layers with light collecting portions. The invention improves light collection efficiency in radiographic imaging by focusing emitted light toward corresponding photoelectric conversion elements. This patent has 5 claims and covers technology applicable to radiographic X-ray apparatus.

Physiological Parameter Sensing Alert System with Activity-Based Alert Adaptation

The USPTO granted Royal Philips N.V. Patent US12588875B2 for a physiological parameter sensing system that combines physiological sensor signals with activity monitoring to determine when additional measurements are recommended. The system generates alerts with characteristics adapted to the user's current activity type and level to ensure alerts are perceived without causing annoyance. The patent includes 12 claims and was filed December 10, 2019.

X-ray System and Method for Tissue Structural Analysis and Imaging

USPTO granted patent US12588883B2 to EosDx Inc. for an X-ray system combining mammography with absorption contrast imaging and diffractometer to analyze breast tissue structure and identify potential cancer sites. The patent, with 20 claims, names inventors Alexander P. Lazarev and Pavel Lazarev, and was filed July 13, 2023.

Radiation detection apparatus with dual sensor panels

USPTO granted Patent US12588879B2 to Canon Kabushiki Kaisha for a radiation detection apparatus featuring dual sensor panels with a separable adhesive coupling mechanism. The invention, filed by Daiki Nakagawa et al., enables damage-free separation of sensor panels under stimulation and has applications in CT apparatus.

Illinois GIPA Genetic Privacy Case - No Liability Without Employment Harm

A federal court in Illinois granted summary judgment to AbbVie in Daniel Henry v. AbbVie, Inc., finding no GIPA violation despite a third-party nurse allegedly asking about family medical history during a pre-employment exam. The court held that requesting genetic information is not actionable under GIPA when the applicant's refusal had no bearing on employment decisions.

Stark Law SRDP Podcast Covers Physician Referral Prohibitions

McDonald Hopkins published Episode 8 of the Legal Diagnosis podcast, featuring healthcare attorneys Liz Sullivan and Emily Johnson discussing the Stark Law and Strategic Self-Referral Disclosure Protocol (SRDP). The podcast explains the strict-liability nature of the Stark Law, which prohibits physicians from referring Medicare or Medicaid patients for Designated Health Services to entities with which they have a financial relationship unless a specific exception applies. The episode is targeted at healthcare providers and legal professionals seeking to understand federal physician self-referral prohibitions.

Vermont AG Settles with UCS - Healthcare Provider Settlement

The Vermont Attorney General's Medicaid Fraud and Residential Abuse Unit settled with United Counseling Service of Bennington County for $483,464 over allegations of service failures and safety risks to Medicaid recipients. The settlement requires extensive organizational reforms including a development services oversight monitor and a new director of quality position. This highlights state AG focus on False Claims Act liability and public safety risk management for healthcare organizations serving vulnerable populations.

Alabama Office-Based Surgery Regulations - Three-Tier System

The Alabama Board of Medical Examiners finalized comprehensive overhaul of Office-Based Surgery (OBS) regulations, effective March 16, 2026, with full compliance required by January 1, 2027. The rules establish a new three-tier classification system (Levels I, II, III) based on procedural risk and depth of anesthesia, replacing regulations unchanged since 2003. Registration now applies to both physicians and physician offices.

New Medicare Advantage Compliance Program Guidance

The OIG released new Industry Segment-Specific Voluntary Compliance Program Guidance (ICPG) for Medicare Advantage Organizations (MAOs) for the first time in over two decades. The guidance identifies seven key risk areas including access to care, marketing and enrollment, and utilization management. This voluntary, nonbinding guidance is intended to complement CMS regulations and signal OIG enforcement priorities to the MA industry.

Healthcare Regulatory Developments Newsletter

JD Supra Healthcare newsletter summarizing March 2026 regulatory developments: FTC announces new healthcare task force for anticompetitive enforcement; bipartisan House bill proposes waiving $100,000 H-1B visa application fees for foreign healthcare professionals; HHS engages pharmaceutical companies on Most Favored Nation drug pricing legislation; PCMA seeks rollback of Labor Department PBM price transparency rule; and Supreme Court ruling pending on False Claims Act qui tam provisions.

Mindara Modern Psychiatry Trademark Application

Mindara LLC filed an Intent to Use trademark application (TM99526630) with the USPTO on December 3, 2025, for 'MINDARA MODERN PSYCHIATRY' covering psychiatric services (Class 44). The application remains pending as of March 30, 2026.

Kitsune Acupuncture and Holistic Beauty Trademark

The USPTO published trademark application TM99526920 for "KITSUNE ACUPUNCTURE AND HOLISTIC BEAUTY" covering acupuncture services. The trademark was published for opposition on March 30, 2026, opening a period during which third parties may challenge the registration. This is a routine trademark publication notice with no new compliance obligations.

INREBIC Trademark Registration for Pharmaceutical Preparations

USPTO registered trademark TM86690908 for INREBIC on March 30, 2026. The mark covers pharmaceutical preparations for treatment of beta thalassemia, myelodysplastic syndromes, blood diseases, cancer, and cytokine inhibitory drugs. Originally filed July 13, 2015.

Curagen Trademark Application - Wound Dressings

USPTO published trademark application TM99206605 for "CURAGEN" covering adhesive bandages for skin wounds, wound dressings, and medical/surgical dressings. The application was filed May 28, 2025 and published March 30, 2026. The trademark covers Class 10 medical devices for wound care.

Microcyn Intent-to-Use Trademark Application for Disinfectant Products

USPTO received an intent-to-use trademark application for 'MICROCYN' (Serial No. TM99323863) covering all-purpose disinfectants and disinfectants for medical, dental, and veterinary instruments. The application was filed by Microcyn on August 6, 2025. This filing does not grant trademark rights until the mark is used in commerce.

VIAFILL trademark renewal for bone void fillers

USPTO renewed the VIAFILL trademark (TM90272233) for bone void fillers consisting of biological materials. The trademark was originally filed on October 22, 2020. Trademark holders should ensure their IP portfolios remain current through periodic renewals.

VIAMEND trademark renewal for bone void fillers

The USPTO renewed the VIAMEND trademark (Registration TM90191559) for bone void fillers consisting of biological materials. The trademark was originally filed on September 18, 2020, and the renewal was processed on March 30, 2026. This is a routine trademark maintenance action with no new obligations imposed on the trademark holder or affected manufacturers.

Imaging systems with improved accuracy and measurements

USPTO granted patent US12588808B2 to Aliph Medical Inc. covering imaging systems with improved accuracy using synchronized modulators to generate image markers for distortion correction. The patent applies to ocular biometry and topography, including OCT arrangements and on-axis imaging systems for whole-eye imaging.

Vision Test Apparatus and System Patent

USPTO granted patent US12588807B2 to EYEMIKAN BIOTECH INC. on March 31, 2026 for a vision test apparatus combining converging and diverging lenses to form virtual images for vision testing. The patent covers the optical system design and method for conducting vision assessments.

Endoscopic Device with Telescoping Members

USPTO granted patent US12588805B2 to Cook Medical Technologies LLC for an endoscopic device with telescoping members. The invention comprises a handle, an elongate tube, an accessory channel, and a movable slide within a curved track to control channel movement. The patent contains 20 claims.

Connection joint for endoscopes

The USPTO granted patent US12588802B2 to OLYMPUS CORPORATION for a connection joint for endoscopes with 15 claims. The patent, invented by Kazuki Ono, covers a first sleeve design for externally fitting tube end portions with a first pusher and bias releasing mechanism.

Image diagnosis assistance apparatus, endoscope system, image diagnosis assistance method, and image diagnosis assistance program

USPTO granted Patent US12588799B2 to FUJIFILM Corporation on March 31, 2026. The patent covers an image diagnosis assistance apparatus and endoscope system that performs region-of-interest recognition using both screen display and audio reporting, with audio reporting levels adjusted based on examination status determination. The patent contains 12 claims and was assigned to inventor Toshihiro Usuda.

Endoscope treatment tool

USPTO granted Patent US12588800B2 to Olympus Corporation for an endoscope treatment tool featuring a tubular distal-end member, outer sheath with channel, treatment-tool body with bendable insertion portion, and rotating member with through-hole. The invention enables guided treatment along a curved locus when pushed in the longitudinal direction. Patent has 13 claims and covers CPC classifications including A61B 1/018 and A61B 17/29.

Endoscope bending section

USPTO granted patent US12588804B2 to Cook Medical Technologies LLC for an endoscope bending section capable of bending in four directions independent of the viewing configuration. The patent includes 19 claims covering continuous and discontinuous rib designs that allow accessory channels to move laterally within the device interior cavity.

Squaremind Trademark Application - Medical Services

USPTO published trademark application TM99513703 for SQUAREMIND in Class 044 (Medical Services) under Intent to Use designation. The application covers medical imaging, telemedicine, medical software development, and healthcare consulting services. The publication date is March 30, 2026, starting a 30-day opposition period.

Rugged Mind and Body Trademark - Mental Health Services

The USPTO published trademark application TM99540083 for RUGGED MIND AND BODY covering mental health services (Class 44), filed December 10, 2025. The publication initiates the standard 30-day opposition period during which third parties may challenge the registration. No compliance actions are required from the public or regulated entities.

CHARLOTTE GASTRO medical trademark publication

The USPTO published CHARLOTTE GASTRO (TM99525728) for opposition on March 30, 2026. The trademark covers medical services including medical diagnostic services, medical research, and providing medical research information. The application was filed December 2, 2025. This is a routine trademark publication notice with no new compliance obligations.

THE LAB. VITALITY CLUB Trademark Application TM99518294

USPTO received trademark application TM99518294 for 'THE LAB. VITALITY CLUB' filed November 26, 2025, covering medical, fitness, and wellness services including health clubs, personal training, dietary guidance, physical therapy, and medical services. The application is filed on an Intent to Use basis with no compliance obligations imposed on other entities.

Bimodal Consciousness Integration System trademark, mental health services

USPTO published trademark application TM99525820 for "BCIS/BIMODAL CONSCIOUSNESS INTEGRATION SYSTEM" covering consulting services in mental health and wellness. The application was filed on December 2, 2025, as an Intent to Use filing. No opposition period or compliance requirements are currently triggered for third parties.

Expandable body device and method of use for aneurysm treatment

USPTO granted Patent US12589014B2 to Artio Medical, Inc. for an expandable body device (ballstent/blockstent) and delivery catheter system designed to treat saccular vascular aneurysms and occlude blood vessel segments. The patent covers devices comprising gold, platinum, or silver that can be compressed, positioned, and expanded to conform to aneurysm shapes, with external surfaces configured to promote thrombosis and tissue ingrowth.

Fluid Collection Assemblies with Movement Enhancing Features

USPTO granted patent US12589022B2 to PureWick Corporation on March 31, 2026, covering fluid collection assemblies with movement enhancing features. The patent includes 20 claims and names 8 inventors including Dana Ahmad Abdelal and others. This grant establishes PureWick's intellectual property rights for the described medical fluid collection technology.

Modified jaw thrust appliance

USPTO granted patent US12589019B2 to inventors Manu Sethi and Sangeetha Sethi for a modified jaw thrust appliance, a medical device for jaw repositioning. The patent includes 19 claims covering an adjustable slidable bottom mechanism, ergonomic thumb piece, inverted U-shaped base with padded back facing, and curved front facing design. This patent grants exclusive rights to the inventors for the disclosed device configuration.

VENTRIC HEALTH Trademark Application - Cardiovascular Diagnostics

USPTO received trademark application TM97784669 for 'VENTRIC HEALTH' filed by Ventric Health LLC on February 7, 2023, covering medical instruments for cardiovascular diagnostics. The application is filed under Intent to Use provisions, indicating the applicant plans to use the mark in commerce.

LL AESTHETICS Trademark Application - Medical Aesthetics Services

USPTO published trademark application TM99513336 for LL AESTHETICS covering medical aesthetics services including cosmetic laser treatments, dermal filler injections, and laser hair removal. The application was filed November 24, 2025, and is now in the opposition period where third parties may file challenges.

Orthoma Orthopedic Urgent Care Trademark Application

USPTO received a trademark application (TM99518201) for 'Orthoma Orthopedic Urgent Care' filed by Orthoma on November 26, 2025. The application covers medical services including urgent care centers and orthopedic care, filed under Intent to Use provisions.

LEADING MDS Medical Services Trademark Registration

USPTO published LEADING MDS trademark application (TM99513598) for opposition on March 30, 2026. The application covers medical services including mental health, behavioral health, telemedicine, weight loss, nursing, and wellness consultations under Class 044. Third parties have the opportunity to file an opposition if they believe the mark would cause confusion with existing marks.

Wildhaven Therapy trademark published for opposition

The USPTO published Wildhaven Therapy's trademark application (TM99513466) for opposition on March 30, 2026. The trademark covers mental health therapy services including psychotherapy, ketamine treatment, and EMDR therapy. Third parties have until April 29, 2026 to file opposition if they believe the mark would cause confusion or harm.

Precision Ocular Network Trademark - Medical Services (Class 044)

USPTO filed a trademark application (TM99513500) for 'Precision Ocular Network' under Intent to Use provisions, covering medical training in ocular health, ophthalmic tissue banking services, and healthcare services involving eye tissue donations. The application was filed November 24, 2025, and covers services provided via networks of eye banks, physicians, and vision scientists.

Rapid Mobile Care Trademark Application for Mobile Healthcare Services

USPTO received trademark application TM99513477 for 'RAPID MOBILE CARE' covering mobile healthcare services, emergency medical services, and health care. The application is filed under Intent to Use basis, with a priority date of November 24, 2025.

LL Aesthetics Nurse Injector Trademark Application - Class 44

The USPTO published trademark application TM99513473 for LL AESTHETICS NURSE INJECTOR covering Class 44 medical and cosmetic services including dermal fillers, botulinum toxin treatments, laser procedures, and health spa services. The application was filed on November 24, 2025, and published on March 30, 2026, initiating a 30-day opposition period during which third parties may challenge the registration.

Central Washington Physical Therapy Trademark Application

USPTO published trademark application TM99513465 for 'CENTRAL WASHINGTON PHYSICAL THERAPY' in Class 044 (Medical Services). The application was filed on November 24, 2025, and published on March 30, 2026, initiating a 30-day opposition period. Third parties who believe this mark would cause confusion with their existing trademarks may file an opposition.

Wednesday Health Intent to Use Healthcare Trademark

The USPTO received a trademark application (TM99513455) from Wednesday Health for an Intent to Use filing covering medical services including concierge medicine, clinical consultation, health assessment, and clinic services. The application was filed on November 24, 2025, and is currently pending review.

Intent to Use Trademark Application - Kaiser Permanente Enterprises

USPTO received an Intent to Use trademark application (TM99513331) from Kaiser Permanente Enterprises for medical and healthcare services under Class 044. The application covers telehealth, telemedicine, hospital services, medical clinic services, prescription pharmacy, mental health, and home health care services. Filing was completed on November 24, 2025.

Proventus medical compression system trademark intent-to-use application

USPTO received Intent-to-Use trademark application TM87764961 for PROVENTUS covering medical compression devices including pneumatic compression systems, therapeutic hot/cold wraps, and acupressure compression wraps. The application was filed on January 22, 2018, by an unidentified applicant seeking to register the mark for Class 10 medical devices.

Bipolar Mapping Suction Device Patent Grant

The USPTO granted Patent US12588868B2 to Inomed Medizintechnik GmbH for a bipolar mapping suction instrument used in surgery. The device monitors nerve tissue while suctioning fluids and tissue. The patent includes 17 claims covering the instrument's dual-pole electrical system and concentric tube design with insulation between cannulas.

Optimizing checkpoint locations for medical instrument insertion trajectory

The USPTO granted Patent US12588874B2 to XACT Robotics Ltd. covering computer-implemented methods and systems for optimizing checkpoint locations along medical instrument insertion trajectories in image-guided procedures. The patent, with 20 claims, relates to model-based determination of optimal checkpoint positions using data from automated medical devices.

Occlusive implant compositions for vas-occlusive contraception

USPTO granted patent US12589182B2 to University of Virginia Patent Foundation for occlusive implant compositions used in non-surgical vas-occlusive contraception. The patent covers methods of percutaneously delivering occlusive substances into the vas deferens under ultrasound guidance, including reversal methods. Inventors: John C. Herr, Alexander L. Klibanov, Kevin Simon Eisenfrats. Filing date: December 29, 2023. 15 claims.

Contraceptive device patent granted to POLY-MED, Inc

The USPTO granted US Patent 12,589,068 B2 to POLY-MED, Inc. on March 31, 2026, covering a contraceptive medical device. The device includes a polymeric ring, porous barrier material, and injection molding guide, with optional active agent administration capability. The patent was filed November 11, 2020, with five named inventors and contains 15 claims.

Hydrogels for in situ-forming tissue constructs

USPTO granted Patent US12589188B2 to The Board of Trustees of the Leland Stanford Junior University covering compositions and methods for corneal hydrogel tissue constructs using in situ-forming IPN and semi-IPN hydrogels for lamellar and defect reconstruction of corneal stromal tissue. The patent names eight inventors including David Myung and Sarah Heilshorn, contains 19 claims, and issued March 31, 2026.

Eagleville Health Behavioral Health Services Trademark Application

EAGLEVILLE HEALTH filed trademark application TM99513225 with the USPTO for behavioral health services under Class 044 (Medical Services). The application was submitted on November 24, 2025, on an intent-to-use basis with a March 30, 2026 deadline to either declare use or request extension. This is a routine trademark registration filing with no new compliance obligations for other parties.

NEW VISION MEDICAL trademark application for medical services

USPTO published trademark application TM99513289 for "NEW VISION MEDICAL" in Class 44 (Medical Services) on March 30, 2026. The application, filed November 24, 2025, covers ambulatory health care facility, medical clinics, and medical group services. The 30-day opposition period began on the publication date.

VARMED HEALTH CENTER Trademark Publication

The USPTO published VARMED HEALTH CENTER (Serial No. TM99513248) for opposition in Class 44 covering health center services, emergency medical services, rehabilitation patient care, medical analysis, and clinic services. Third parties have a 30-day window from publication to file opposition if they believe registration would cause confusion or damage.

Upper Melville Pond Closure Due to PFAS Contamination

The Rhode Island Department of Health issued an informational notice regarding the closure of Upper Melville Pond due to detected PFAS contamination. The agency is conducting additional testing and investigation to assess the extent of contamination. Residents are advised to avoid swimming, fishing, and other recreational water activities at the pond until further notice.

Oxoid Salmonella 9-0 Recall - Remel/Thermo Fisher Scientific

ANSM issued safety notice R2608613 informing medical biology laboratories of a field safety corrective action by Remel/Thermo Fisher Scientific, involving the recall of 847 units of Oxoid Salmonella agglutinating sera (Salmonella 9-0). Affected users received a direct communication from Thermo Fisher Scientific with instructions. Laboratories should verify their inventory for affected lots and contact the manufacturer directly.

GE Healthcare Signa Premier MRI Safety Notice

ANSM informed health facilities and medical imaging centers of a safety action by GE Healthcare regarding the Signa Premier MRI system. The action is registered under reference R2608457. Healthcare providers who received the letter should review and implement the specified safety measures.

MarClamp Cut IQ Safety Notice - KLS Martin Group

ANSM issued safety notice R2608256 regarding KLS Martin Group's MarClamp Cut IQ electrosurgical device with instrument coding 23cm. Hospital pharmacies and healthcare establishments are directed to review and act upon the attached manufacturer safety communication. This is a Class I medical device safety action.

Orbis Medication 3.x Safety Notice - DH Healthcare

ANSM informed healthcare facilities of a safety action (n° R2607882) implemented by DH Healthcare GmbH regarding Orbis Medication 3.x, a computer-aided prescribing software. Users have received direct correspondence from the manufacturer. Healthcare providers using this software should review the attached safety communication.

Recall of Dental Root Canal Instruments - Shenzhen Perfect Medical

ANSM issued safety recall R2606807 for dental root canal instruments manufactured by Shenzhen Perfect Medical Instruments Co., Ltd. The recall involves a lot withdrawal due to identified safety concerns. Healthcare facilities, dentists, and medical professionals using these instruments must identify and remove affected products from use.

Recall of Veos-Kaphron Polyaxial Screwdrivers - Distimp Spinal Equipment

ANSM has issued safety alert R2608136 for a recall of 847 units of Veos-Kaphron polyaxial screwdrivers manufactured by Distimp. This spinal ancillary equipment recall is a mandatory action to remove potentially defective medical devices from use in healthcare facilities. All affected users have received direct notification from Distimp regarding the recall procedures.

Saudi launches food composition database, empowering nutrition awareness

The Saudi Food and Drug Authority (SFDA), through its National Nutrition Committee, launched the Saudi Food Composition Database in collaboration with the Health Sector Transformation Program. The database provides comprehensive nutritional profiles for traditional Saudi foods and local dishes, including calories, macronutrients, vitamins, and minerals. This initiative aligns with Saudi Vision 2030's goals for digital transformation of health and food sectors.

Vanda patents trichostatin A cancer treatment method

USPTO granted patent US12590162B2 to Vanda Pharmaceuticals Inc. covering a method of treating cancer using trichostatin A (TSA). Inventors include Mihael H. Polymeropoulos, Louis William Licamele, and Christian Lavedan. The patent contains 5 claims.

siRNA Septicemia Treatment Patent

USPTO granted Patent US12590304B2 to Suzhou Ribo Life Science Co., Ltd. covering an siRNA therapeutic targeting the kininogen (KNG) gene for treating septicemia. The patent includes 8 claims for the nucleic acid composition, pharmaceutical formulation, and siRNA conjugate. This is a standard patent grant公告 with no regulatory compliance obligations.

EEG-fNIRS neurofeedback system patent granted

The USPTO granted Patent US12588859B2 to the Education University of Hong Kong for an integrated EEG-fNIRS neurofeedback system. The patent covers EEG electrodes, fNIRS detectors, a computation module, and a report generator that processes brain signals and selects a representative score. Invented by Kin Chung Michael Yeung, the patent contains 12 claims and was granted on March 31, 2026.

System and method for intraoperative nerve guidance during surgery

USPTO granted patent US12588860B2 to Neuralytix, LLC covering a system and method for intraoperative nerve guidance during surgical procedures. The patent describes receiving real-time image data from intraoperative imaging, determining nerve function parameters indicative of nerve health, and presenting a concurrent visual output of anatomical structures and nerve health indicators. The patent names inventors David S. Nay and Christopher Wybo, with 19 claims.

PSA Cardiac Activation Detection Method and System

The USPTO granted Patent No. US12588856B2 to Biosense Webster (Israel) Ltd. covering methods for identifying and graphically indicating cardiac tissue locations exhibiting progressively slowing activation (PSA) based on cardiac signal analysis. The patent includes 14 claims and names eight inventors including Tal Haim Bar-On and Kumaraswamy Nanthakumar.

Wearable device and method for non-invasive assessment of glymphatic flow

USPTO granted Patent US12588861B2 to Applied Cognition, Inc. for a wearable head-mounted system that non-invasively assesses glymphatic flow using alternating current electrodes. The system includes a measurement validation module applying Hilbert transform or Kramer-Kronig tests and a cranial fluid dynamics module. The patent contains 20 claims and covers devices and methods for neurological fluid assessment.

Eagleville Hospital Trademark - Behavioral Health Services

The USPTO published Eagleville Hospital's trademark application (TM99513163) for behavioral health services, opening a standard 30-day opposition period during which third parties may challenge the registration. This is a routine trademark prosecution action with no substantive regulatory impact.

STIM MD SaaS trademark for physician bone healing portal

The USPTO received trademark application TM99393212 for STIM MD on September 15, 2025. The application covers SaaS services for physician-patient communications regarding bone healing solutions, including online portals for capturing patient health data and transmitting it to physicians for remote viewing and treatment monitoring. The application was filed under Intent to Use provisions.

ROOTFORGE THERAPY Trademark for Mental Health Services

The USPTO published trademark application TM99512998 for ROOTFORGE THERAPY on March 30, 2026. The application covers mental health therapy services, psychotherapy, and mental health counseling. The 90-day opposition period begins upon publication, during which third parties may challenge the registration.

Trademark Application 99510052 - Medical Services (Class 044)

USPTO recorded Intent to Use trademark application 99510052 for medical services under Class 044. The application covers managed health care services, home health care services, geriatric health care management, and advisory services relating to health care. This is a routine trademark filing record with no new regulatory obligations.

TruGenix Trademark Application - Animal Genetics Services

The USPTO published trademark application TM99463825 for TRUGENIX on March 30, 2026. The application covers downloadable software and services for animal genetic testing, health screening, database management, and veterinary services. The publication initiates a standard opposition period during which third parties may challenge the trademark registration.

COCO WELLNESS SPA Trademark Application

USPTO published trademark application TM99506066 for COCO WELLNESS SPA covering medical spa and health spa services including cosmetic laser treatments, microneedling, IV hydration therapy, body contouring, and hormone replacement consulting. The application was filed on 2025-11-19 and published for opposition on March 30, 2026.

Prism Breathwork Trademark Application for Wellness Services

USPTO received Intent to Use trademark application TM99512817 for 'PRISM BREATHWORK' covering medical/healthcare services in Class 044, including breathwork therapy, energy healing, meditation services, and wellness education. The application was filed by Prism Breathwork LLC and is currently in draft status pending examination.

Meniscal Allograft Transplantation System and Methods

The USPTO granted patent US12588914B2 to Arthrex, Inc. for a meniscal allograft transplantation system and associated methods. The patent, granted on March 31, 2026, covers proprietary orthobiologic technology in the meniscal repair space with 20 claims.

Laser Processing System Test Method Patent Grant

USPTO granted Patent US12589034B2 to Carl Zeiss Meditec AG for a method of system testing laser processing systems. The patent covers a functional test of control elements combined with determination of variable parameters affecting laser processing execution, with overlapping test phases. The patent application was filed March 11, 2022, and contains 18 claims.

Convex ostomy barrier patent granted to Hollister

USPTO granted patent US12589023B2 to Hollister Incorporated on March 31, 2026, for a convex ostomy barrier and method of forming such barriers. The patent covers a skin barrier with inlet opening and convex insert system for attaching ostomy appliances to peristomal skin. Invented by Kenneth Nielsen, the patent includes 6 claims under CPC classifications A61F 5/448 and related codes.

Ocular delivery systems and methods for Schlemm's canal access

The USPTO granted patent US12589024B2 to Sight Sciences, Inc. covering ocular delivery systems and methods for accessing Schlemm's canal and delivering ocular devices or fluid compositions. The technology addresses medical conditions associated with elevated intraocular pressure, including glaucoma. The patent includes 30 claims and names David Y. Badawi, Daniel O'Keeffe, and Paul Badawi as inventors.

Safety vitreous body cutting device

USPTO granted patent US12589029B2 to The Catholic University of Korea Industry-Academic Cooperation Foundation for a safety vitreous body cutting device used in vitreoretinal surgery. The device incorporates a tubular body with negative pressure, a reciprocating cutter, and a safety net to prevent retinal damage during vitreous body removal. The patent (9 claims) was filed on October 25, 2024.

Laser methods and systems for addressing conditions of the lens

The USPTO granted Patent US12589033B2 to Lensar, Inc. on March 31, 2026, covering laser systems and methods for performing cataract surgery. The patent includes claims for using biometric systems to determine material properties of eye structures, laser pulses with varying power levels, and therapeutic laser delivery systems with variable beam power capability.

Bandage System for Detection of S. aureus

The USPTO granted patent US12589035B2 to inventor Emma J Bright on March 31, 2026. The patent covers a disposable adhesive bandage capable of detecting Staphylococcus aureus at wound sites by integrating rapid test technology into the bandage pad. The patent contains 10 claims and grants exclusive rights to this detection technology.

Combined Laser and Phacoemulsification System for Eye Surgery

The USPTO granted Lensar, Inc. Patent US12589031B2 for an integrated laser-ultrasound system combining laser and phacoemulsification for eye surgery. The patent covers systems with safety interlocks preventing simultaneous laser and phaco operation, repositionable laser arms, and 330-degree clocking positioning around the patient eye. The patent contains 36 claims.

Intraocular devices, systems, and methods

USPTO granted patent US12589025B2 to Sight Sciences, Inc. for intraocular implants configured to deliver drugs to the eye for treating eye conditions. The patent has 68 claims and names Paul Badawi, David Y. Badawi, and Daniel O'Keeffe as inventors. Filing date was May 27, 2022, with application number 17827573.

Grasping structure for retinal membrane surgical instrument

The USPTO granted patent US12589028B2 to Alcon Inc. covering an ophthalmic surgical instrument for peeling retinal membranes. The patent includes 17 claims and names Reto Grüebler and Luca Palmerini as inventors. The instrument features a handle with an actuator, outer tube, inner rod, and a grasping structure with first and second polymer arms angled to conform to retinal membranes.

Pen Format Liquid Collection Device

USPTO granted Patent US12588845B2 to University of Tasmania for a pen-format liquid collection device for liquid sampling and analysis. The device features an elongate tubular housing with a liquid take-up element (capillary) and a retention element that protects samples within the housing. The patent includes 41 claims and names 7 inventors including David Charles Bailey and Andrew Gooley.

Analyte sensors and sensing methods featuring dual detection of glucose and ketones

The USPTO granted Patent US12588844B2 to Abbott Diabetes Care Inc. covering analyte sensors capable of dual detection of glucose and ketones. The patent includes 18 claims for sensors with two working electrodes, one with a ketones-responsive enzyme system and one with a glucose-responsive enzyme, each coated with a membrane of different composition. The invention enables concurrent measurement of both analytes from a single sensor device.

Methods and systems for determining brain and nerve function status via pupillary analysis

The USPTO granted Patent US12588846B2 to Hadasit Medical Research Services & Development Ltd. covering methods, systems, and devices for determining brain and/or nerve function status by analyzing pupillary response through closed eyelids. The patent includes 17 claims and covers technology that tracks pupil location, calculates pupil size, and monitors pupillary reflex using transmitted light analysis.

Biomagnetism measuring device and method for controlling biomagnetism measuring device

The USPTO granted Patent US12588847B2 to Shimadzu Corporation on March 31, 2026, covering a biomagnetism measuring device and control method. The invention uses first and second magnetic sensors with optical pumping action via plasma-generated cells, with staggered plasma generation controlled by a power supply controller. The patent contains 6 claims.

Devices and Systems for Measuring Magnetic Fields

USPTO granted patent US12588848B2 to INSERM for a magnetic field measurement device designed for magnetocardiovascular applications. The invention uses ultrasensitive magnetic sensors capable of measuring weak fields in the sub-picotesla range with low-noise processing circuitry. The patent contains 19 claims covering the device design and measurement methods.

Garment medical examination system

USPTO granted patent US12588849B2 to Scientific American Medical Examination Research, LLC for an ECG glove system capable of recording 12-lead electrocardiograms. The patent covers a glove with precordial leads positioned along the peripheral edge and arm leads positioned on both palmar and dorsal sides. Inventor Samer Nasry holds 20 claims for this medical examination garment.

Monitoring and analysis of invasive and non-invasive electrophysiological signals

The USPTO granted Cardioinsight Technologies Inc. Patent US12588850B2 covering a computer-implemented method for monitoring and analyzing electrophysiological signals using both invasive and body surface electrodes. The patent protects technology for reconstructing cardiac electrophysiological signals on surfaces of interest within a patient's body, with geometry data that adapts based on movement of invasive electrodes.

Variable density mapping catheter

The USPTO granted Patent US12588851B2 to St. Jude Medical, Cardiology Division, Inc. for a variable density mapping catheter designed for cardiac electrophysiological mapping. The patent, with 20 claims, covers flexible high-density mapping catheters with electrode arrays for detecting tissue characteristics and diagnosing cardiac arrhythmias such as cardiac arrhythmias.

Neural interface system and method

USPTO granted patent US12588852B2 to Science Corporation for a neural interface system capable of recording electrical signals from neurons and delivering optical/electrical stimuli via LEDs and electrodes. The patent, with 19 claims, covers integrated recording and stimulus modules controlled by digital and analog drive circuitry.

Fusion antibody for presenting antigen-derived T cell epitope

USPTO granted Patent US12590156B2 to AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION for a fusion antibody composition designed to deliver viral antigen-derived CD8+ T cell antigen epitopes to target cell cytoplasm for presentation on major histocompatibility complex class I (MHC-I) molecules. The patent contains 22 claims covering the composition and its use in antigen presentation.

Medical Services Trademark Application - Rooted & Resilient Therapy

The USPTO received trademark application TM99006347 for "Rooted & Resilient Therapy" filed January 17, 2025. The application is an Intent-to-Use filing covering mental health therapy services (Class 044), with an anticipated registration date of March 30, 2026.

1135 Waiver Request Automated Process PRA Information Collection

CMS published a 60-day Federal Register notice announcing an opportunity for public comment on a revision to the Submission of 1135 Waiver Request Automated Process information collection (OMB Control No. 0938-1384). The collection supports the Acute Hospital Care at Home (AHCAH) program. Comments must be submitted by June 1, 2026.

Analyte Sensor with Integrated Components Patent Grant

The USPTO granted Patent US12588843B2 to Medtronic MiniMed, Inc. covering analyte sensor devices with integrated electrical and chemical components fabricated on a substrate. The patent includes 29 claims and relates to continuous glucose monitoring technology.

Blood oxygen concentration measurement device and method

USPTO granted patent US12588840B2 to Quanta Computer Inc. on March 31, 2026, covering a blood oxygen concentration measurement device with light source, detection, signal processing, and control units. The patent includes 12 claims for calculating blood oxygen values, pulse rate, and signal strength index, with low perfusion measurement capabilities.

Photometry Device for Bloodstream Oxygen Measurement Using Dual LED Configuration

USPTO granted Analog Devices International Unlimited Company Patent No. US12588842B2 for a photometry device using dual LED configuration with an inductor for measuring oxygen in a patient's bloodstream. The patent (18 claims) covers systems and methods for emitting light to a target via first and second LEDs with energy storage capability.

Calibration-free pulse oximetry

The USPTO granted Patent US12588841B2 to Viavi Solutions Inc. on March 31, 2026, covering calibration-free pulse oximetry devices and methods. The patent (20 claims) describes devices and methods for calculating arterial oxygen saturation using photoplethysmography (PPG) data analysis without requiring traditional calibration. Inventors: Lan Sun, Chang Meng Hsiung, Babs Soller.

Polymorph of EP4 receptor antagonist, preparation method and use

USPTO granted patent US12590103B2 to Shanghai Yuyao Biotech Ltd. for a stable polymorph of an EP4 receptor antagonist. The patent covers the solid-state form with improved stability over the amorphous compound, with claims directed to oncology, immunology, and bone disease applications.

OTTO BOCK Prosthetic Hand Patent Grant

The USPTO granted patent US12589011B2 to OTTO BOCK HEALTHCARE PRODUCTS GMBH for a prosthetic hand design featuring a chassis with longitudinal guide and clamping element. The patent, filed June 11, 2021 as Application No. 18001426, contains 20 claims covering the mechanical assembly that blocks two translational degrees of freedom in a locking position.

Stent delivery system, endoscope system, and stent indwelling method

USPTO granted Patent US12589015B2 to Olympus Corporation for a stent delivery system, endoscope system, and stent indwelling method. The patent covers a system with an outer tube and inner tube configured for insertion into an endoscope channel, with a stent stored between them. The patent application 17888695 was filed August 16, 2022, and includes 19 claims.

Fully crimped stent for treating bifurcations

The USPTO issued patent US12589013B2 to Advanced Bifurcation Systems Inc. on March 31, 2026. The patent covers a fully crimped stent delivery system for treating bifurcated vessels, including features to prevent axial movement during delivery. The patent includes 10 claims and names inventors Ashur Bourang and Henry Bourang.

Spiromacrocyclic orexin 2 receptor agonists

USPTO granted Patent No. US12590106B2 to H. Lundbeck A/S for novel spiromacrocyclic orexin 2 receptor agonists used in CNS treatments. The patent, covering 18 claims, names 11 inventors including Karsten Juhl, Wanwan Yu, and Thomas Leegaard Andersen, with application originally filed as EP19195185.

KRas G12C inhibitors for cancer treatment

The USPTO granted patent US12590105B2 to Eli Lilly and Company on March 31, 2026, covering 24 claims for KRas G12C inhibitors and their use in treating cancer. The patent, with application number 18255713 filed on November 24, 2021, protects specific compound formulations and methods of treatment. This grant provides Eli Lilly with enforceable intellectual property rights in the United States.

Corrosion inhibitor formulations with pyridinium and hydroxy substituents

The USPTO granted patent US12590256B2 to Saudi Arabian Oil Company on March 31, 2026, covering corrosion inhibitor formulations containing compounds with both pyridinium and hydroxy substituents. The patent includes 6 claims and covers methods of making the compounds and processes for inhibiting corrosion on metallic surfaces. Inventors include Muhammad Imran Ul-haq, Nayef M. Alanazi, Turki M. Al Abeedi, Abdullah Al-Malki, and Faisal M. Al-Mutahhar.

CD30+ Cancer Detection and Treatment Methods Patent

USPTO granted Patent US12590968B2 to Seagen Inc. for methods of diagnosis, prognosis, prophylaxis and treatment of CD30+ cancers. The patent (Kind B2), with inventors Tina Albertson and Maria L. Smith, contains 4 claims covering CPC classifications A61K 47/6849, C07K 16/2878, and A61P 35/00. Application No. 17747591 was filed May 18, 2022.

Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof

USPTO granted Regeneron Pharmaceuticals Patent No. US12590168B2 covering CD38/CD28 bispecific antibodies designed to activate T-cells and inhibit tumor growth. The patent includes 35 claims and covers methods for treating cancers including multiple myeloma, lymphoma, and leukemia using bispecific antigen-binding molecules.

Combination therapies against cancer targeting CD38 and TGF-β

USPTO granted Sanofi Patent US12590167B2 covering combination cancer therapies targeting CD38 and TGF-β using specific antibodies. The patent (11 claims) was granted March 31, 2026, with a filing date of July 10, 2019. This patent relates to compositions and methods for treating cancer using dual-antibody therapy.

California Hospice Fraud Investigation

The U.S. House Committee on Oversight and Government Reform, led by Chairman James Comer, has launched an investigation into California hospice fraud, sending a document request to Governor Gavin Newsom on March 23, 2026. The committee alleges $105 million in Medicare overbilling by Los Angeles County hospice providers and documents a 1500% increase in hospice providers between 2010-2022. California officials have responded that they have already revoked 280+ licenses and have hundreds more under investigation.

Brain-computer interface legal readiness, FDA regulation, neural data privacy

This legal analysis article examines the evolving regulatory landscape for brain-computer interfaces (BCIs), noting that Neuralink received FDA approval for human trials in 2023 under its PRIME Study and is enrolling 21 participants as of early 2026. The article discusses FDA device classification pathways, neural data privacy concerns, and competitive pressures from Samsung and Chinese research teams.

Assignment of Benefits in Payer Disputes - Federal Court Ruling

The U.S. District Court for the District of Connecticut issued a ruling in Abira Medical Laboratories LLC v. Aetna Inc. et al. clarifying that explicit assignment language conveying 'all rights and benefits' under health plans is sufficient to establish standing to sue in payer disputes, while power-of-attorney language alone does not permit the grantee to bring suit. The court allowed breach of contract claims to proceed for a subset of claims and limited state-law claims to non-ERISA plans.

Medicare NPI and Attestation Rules for Hospital Off-Campus Departments

CMS will implement new Medicare attestation requirements for off-campus hospital outpatient departments under Section 6225 of the Consolidated Appropriations Act, adding Section 1833t(23) to the Social Security Act. Beginning January 1, 2028, off-campus departments paid under OPPS must bill under their own location-specific NPI and submit provider-based attestations demonstrating compliance with 42 C.F.R. § 413.65 between January 1, 2026 and December 31, 2027. All previously excepted or grandfathered sites are included.

Executive Order Establishes Fraud Task Force Targeting Federal Benefit Programs

President Trump signed an Executive Order creating a Task Force to Eliminate Fraud within the Executive Office of the President. The Task Force, chaired by the Vice President with the FTC Chairman as Vice Chairman, will coordinate a national strategy to combat fraud in federal benefit programs including housing, food assistance, medical care, and cash assistance. Federal agencies administering benefit programs must identify fraud-vulnerable transactions within 30 days, with minimum anti-fraud requirements due within 60 days.

Florida Medicaid Fraud Investigation Under Trump Administration Scrutiny

CMS Administrator Dr. Mehmet Oz has initiated a Florida Medicaid fraud investigation as part of a broader Trump Administration effort to identify excessive spending and reduce waste and abuse. Florida officials have 30 days to respond to questions regarding Medicaid program integrity, Medicaid provider oversight, and determination of high-risk Medicaid services. Healthcare facilities and practitioners should prepare for potential enhanced enforcement including increased audits, prepayment reviews, and provider revalidations.

SOPs for Controlled Drugs in Registered Care Facilities - Northern Ireland

The Regulation and Quality Improvement Authority (RQIA) published guidance to help registered care facilities in Northern Ireland develop Standard Operating Procedures (SOPs) for the management of controlled drugs. The guidance implements requirements under the Health Act 2006 and the Controlled Drugs (Supervision of Management and Use) Regulations (NI) 2009, which were introduced following the Fourth Report of the Shipman Inquiry. Care homes, nursing homes, and children's homes must have written SOPs covering access, storage, security, disposal, and record-keeping for controlled drugs.

Fezolinetant (Veoza) for Menopause Vasomotor Symptoms

NICE published technology appraisal guidance TA1143 recommending fezolinetant (Veoza) as an option for treating moderate to severe vasomotor symptoms associated with menopause. The guidance applies to women who have had a breast cancer diagnosis where hormone replacement therapy is contraindicated. NHS commissioners must make funding available within 3 months of publication date.

New Jersey Adds CCBHC Services and Payment Methodologies

CMS approved New Jersey's Medicaid State Plan Amendment (SPA 25-0017) to add Certified Community Behavioral Health Clinic (CCBHC) services and establish payment methodologies for these services. The amendment was approved on March 27, 2026, with an effective date of October 1, 2025. CCBHCs provide integrated behavioral health services to individuals with mental health and substance use disorders.

California Medicaid DRG Payment Parameters Update

CMS approved California State Plan Amendment CA-25-0022, updating DRG payment parameters for State Fiscal Year 2025-26 for general acute inpatient services. The amendment affects private hospitals, non-designated public hospitals, out-of-state hospitals, and critical access hospitals. A companion letter clarifies that CMS is not approving payment methodologies that may violate the Asante v. Kennedy circuit court opinion.

Vermont Mental Health Services State Plan Amendment

CMS approved Vermont State Plan Amendment 25-0009, which transfers rehabilitation mental health services from the Global Commitment to Health 1115 waiver to the State Plan. The amendment, effective July 1, 2025, updates Vermont's Community Mental Health Center services under 42 CFR §440.130.

GENEFLUENCE Trademark Application for Marketing and Medical Services

USPTO received trademark application TM98589024 for GENEFLUENCE filed under Intent to Use basis. The application covers medical and health services including DNA/mRNA/epigenetic testing, health screening, dermatology services, and digital health platforms, as well as associated marketing and retail services for beauty products, supplements, and consumer merchandise.

Medical Services Trademark Application - Ophthalmology

USPTO received trademark application TM98947948 for 'MY EYELID SURGEON' filed by a medical practice. The application covers ophthalmology services and treatment of eye diseases and conditions under Class 044 (Medical Services). The filing basis is Intent to Use, indicating the applicant plans to use the mark in commerce in the future.

Wearable device for differential measurement on pulse rate and blood flow

USPTO granted patent US12588820B2 to OMNI MEDSCI, INC. (inventor Mohammed N. Islam) on March 31, 2026. The patent covers a wearable device with biosensors, LED light sources, and AI-based analysis for measuring pulse rate and blood flow through differential optical measurement.

OCT catheter with low refractive index optical material

The USPTO granted Patent US12588819B2 to Elumn8 Medical, Inc. for an OCT catheter with low refractive index optical filler material designed to reduce imaging artifacts during medical procedures. The patent covers 26 claims relating to catheter devices combining imaging and intervention capabilities with a tapered distal end serving as a crossing tool for occluded vessels. Inventors include John B. Simpson, Kin Foong Chan, Wendy Lam, Sergio Salinas, and Evangeline Lumabas.

EGFR Bispecific Antibody Patent Grant - Amunix Pharmaceuticals

The USPTO granted patent US12590159B2 to Amunix Pharmaceuticals covering compositions targeting EGFR, including protease-activatable bispecific fusion proteins such as T cell engagers. The patent includes 8 claims for antibody binding domains targeting CD3 and EGFR, cleavable linker sequences, and methods of treatment for conditions such as cancer.

Antibodies binding to citrullinated histone 2A and/or 4

USPTO granted Patent No. 12,590,143 B2 to Citryll B.V. for antibodies binding to citrullinated histone 2A and/or 4, covering therapeutic applications for Neutrophil Extracellular Trap (NET)-associated pathologies. The patent includes 13 claims and covers both the antibodies and binding fragments for use in treatment.

CD3-specific binding molecules

The USPTO granted Immunocore Limited Patent US12590152B2 covering CD3-specific binding molecules, specifically antibodies and fragments with improved properties. The patent contains 19 claims and names 8 inventors including Martina Canestraro and Stephen Harper. This is a routine patent grant establishing intellectual property rights without regulatory compliance obligations.

Bi-specific Chimeric Antigen Receptor for TGF-beta Binding

USPTO granted patent US12590145B2 to The Regents of the University of California on March 31, 2026, covering a bi-specific chimeric antigen receptor (CAR) that specifically binds TGF-beta. The CAR technology neutralizes TGF-beta while simultaneously triggering T-cell activation, converting an immunosuppressive signal into an activating stimulus. The patent contains 10 claims with application number 17323568, filed May 18, 2021.

GLP-1 agonist polypeptide compound and salt thereof, synthesis method therefor and use thereof

USPTO granted patent US12590134B2 to SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD. for a GLP-1 agonist polypeptide compound (SEQ ID NO: 1) used in diabetes and obesity treatment. The patent includes 2 claims covering the compound, salt forms, synthesis method, and therapeutic applications. Filing date was August 17, 2022, under application number 17820251.

Anti-C-MPL antibody and use thereof

USPTO granted patent US12590161B2 to Daegu Gyeongbuk Institute of Science and Technology for an anti-C-MPL antibody (2R13) that increases platelet production through megakaryocyte maturation. The antibody offers longer half-life than conventional therapeutic agents with lower self-antibody production and reduced immunogenicity. The patent covers therapeutic applications for chronic or complication-induced immune thrombocytopenia.

Anti-Henipavirus Monoclonal Antibodies with Broad Spectrum Neutralization

The USPTO granted Patent US12590141B2 to the Academy of Military Medical Science covering monoclonal antibodies targeting Henipavirus glycoprotein G. The patent claims antibodies combining macaque variable regions with human constant regions, demonstrating broad neutralization activity against Nipah and Hendra viruses. The patent includes 9 claims and covers encoding nucleic acids for therapeutic applications.

PD-L1 Binding Molecules and Uses Thereof

USPTO granted Patent US12590155B2 to Beijing Mabworks Biotech Co., Ltd. for molecules (single-domain antibodies and heavy chain only antibodies) that specifically bind human PD-L1 for use in treating tumors and related diseases. The patent contains 17 claims and covers the分子的 therapeutic applications in cancer treatment.

Gilead PD-1/PD-L1 inhibitors, cancer treatment compounds

USPTO granted Gilead Sciences, Inc. Patent US12590062B2 for PD-1/PD-L1 inhibitor compounds for cancer treatment. The patent covers compounds according to formula (I), methods of using said compounds singly or in combination with additional agents, and compositions for treating cancer. Application No. 17098171 was filed November 13, 2020, and the patent contains 18 claims.

Crystalline acetylcholinesterase inhibitor forms A, B, C for neurodegenerative diseases

USPTO granted Patent US12590061B2 to Shanghai Institute of Materia Medica, Chinese Academy of Sciences covering crystalline forms A, B, and C of an acetylcholinesterase inhibitor compound (2-((1-(2-fluorobenzyl)-4-fluoropiperidin-4-yl)methylene)-5,6-dimethoxy-2,3-dihydro-1-indanone). The patent, filed November 24, 2020 as Application No. 17780449 with 10 claims, protects the stable, low-hygroscopicity crystalline forms used for preventing and treating neurodegenerative diseases.

GLP-1/GIP Dual Agonist Patent for Diabetes Treatment

USPTO granted patent US12589158B2 to Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. for long-acting GLP-1/GIP dual agonist compounds for treating Type II diabetes mellitus. The patent covers compounds with dual agonistic effects on glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors.

Benzimidazole and Benzimidazolone Based PROTAC Compounds for LRRK2 Degradation

The USPTO granted Arvinas Operations, Inc. patent US12589156B2 covering benzimidazole and benzimidazolone PROTAC compounds designed to recruit LRRK2 protein to E3 ubiquitin ligase for targeted degradation. The patent contains 12 claims and was filed on March 24, 2025.

Use of D9-methadone for postoperative pain relief

USPTO granted Patent US12590054B2 to the Board of Regents, The University of Texas System, covering the use of d9-methadone as an alternative formulation for methadone with improved pharmacokinetic properties for postoperative pain relief. The patent includes 15 claims and covers compositions and methods for managing pain following injury, disease, or surgery.

4C Medical Prosthetic Heart Valve

The USPTO granted patent US12588998B1 to 4C Medical Technologies, Inc. for a collapsible and expandable prosthetic heart valve implant designed for implantation in a heart chamber. The patent includes 126 claims and was filed on April 23, 2025 under Application No. 19187060. Inventors are Saravana B. Kumar, Steven D. Kruse, and Jason S. Diedering.

Systems and methods for preparing a meniscal tissue for implant

The USPTO granted patent US12589002B2 to Arthrex, Inc. on March 31, 2026. The patent covers systems and methods for preparing meniscal tissue for implant, including meniscal allografts with bone blocks and techniques for shaping them using clamp and jig arrangements. Shane Noble is listed as lead inventor alongside four co-inventors, with 14 claims total.

Spinal Interbody Spacer Patent Grant - Astura Medical

The USPTO granted Patent US12589003B2 to Astura Medical Inc. for a spinal interbody spacer featuring an asymmetrical open end, asymmetrical screw fixation plate, and locking mechanism. The patent covers 14 claims and names inventors Ross Dusterhoft and Thomas Purcell. The patent expires June 29, 2043 based on the filing date of June 29, 2023.

Patient-Specific Total Disc Replacement Spinal Implant Patent

USPTO granted Patent US12589004B2 to Nexus TDR, Inc. for a patient-specific total disc replacement spinal implant system. The patent covers methods for tailoring spinal implants to individual patient needs by pre-operative evaluation and modifying implant flexure features. Assignee: Nexus TDR, Inc.; Inventors: David T. Hawkes, Peter Halverson.

Bone Fusion Method and System for Sternal Closure

The USPTO granted Patent US12588999B2 to THORAGENIX INNOVATIONS, INC. covering systems and methods for fusing bone sections using sternal wires and harvested cancellous bone tissue to create a sternal construct acting as a bone gasket for improved healing.

Expandable vertebral implant and method

USPTO granted patent US12589006B2 to SeaSpine Orthopedics Corporation on March 31, 2026, covering an expandable vertebral implant system with multi-core architecture, gear-driven expansion, and polyaxial endplate configurations for spinal fusion procedures. The patent includes 42 claims and names Michael Roscoe Harper, Samuel Hunter Hatcher, and Adam James Lipson as inventors.

Adjustable Interbody Spinal Cage Patent Grant

The USPTO granted Patent US12589005B2 on March 31, 2026 to inventors Nazmi Peyman, Edmond Zahedi, and Steven Fiore for an adjustable interbody spinal cage. The device features telescoping tubes with actuators and retention members that can be operated non-invasively after implantation. The patent includes 5 claims covering the flexible shell, variable-length rods, and adjustment mechanisms.

Intradiscal fixation systems

USPTO granted Globus Medical, Inc. Patent No. US12589007B2 for intradiscal fixation systems used in spinal disc repair. The patent covers expandable implants and flexible anchors with shape-memory materials, with 9 claims. Inventors include Myles Sullivan, Carly Taubenkraut, and Mark Weiman.

Dynamic implant fixation plate

USPTO granted patent US12589008B2 to NANOHIVE MEDICAL LLC for a dynamic implant fixation plate designed to reduce stress shielding and permit enhanced loading of implant sites. The patent covers the plate mechanism and compatible implant configuration allowing multi-plane fixation with relative motion capability. The grant includes 18 claims with 8 listed inventors.

Expandable fusion device with integrated deployable retention spikes

The USPTO granted Globus Medical, Inc. Patent US12589009B2 for an expandable spinal fusion device featuring integrated deployable retention spikes designed to resist expulsion when implanted in the intervertebral disc space. The patent covers the device's actuator assembly and sidecar assembly with pivotable upper and lower spikes. Three inventors are credited: Catherine Krawiec, Damien Kahmer, and George Yacoub.

Compounds for the treatment of neurodegenerative and metabolic disorders

USPTO granted Patent US12590094B2 to University of Florida Research Foundation for heterocyclic compounds targeting neurodegenerative diseases linked to protein misfolding, including Alzheimer's, Parkinson's, ALS, and prion diseases, as well as metabolic disorders. The patent covers 8 lead compound series demonstrating NAD-restoring properties and therapeutic efficacy in cellular and animal models.

Crystalline Forms of Orally Available Selective KIT and PDGFR Kinase Inhibitor

USPTO granted patent US12590095B2 to Sandoz AG on March 31, 2026, covering crystalline forms of avapritinib, a KIT and PDGFR kinase inhibitor. The patent (CPC C07D 487/04) protects polymorphs and hydrates of the compound for treating gastrointestinal stromal tumors (GIST) and advanced systemic mastocytosis (AdvSM). Inventors include Verena Adamer, Andrea Thaler, and Erwin Schreiner.

Imidazo[2,1-f][1,2,4]triazin-4-amine as TLR8 agonists for cancer treatment

USPTO granted Patent US12590096B2 to BeOne Medicines GmbH for an imidazo[2,1-f][1,2,4]triazin-4-amine derivative as a TLR8 agonist for treating cancers. The patent contains 18 claims and was filed on July 31, 2020 (Application No. 17632027). The compound is classified under 12 CPC codes spanning antineoplastic, antiviral, and anti-inflammatory applications.

Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same

The USPTO granted Patent US12590098B2 to Axceso Biopharma Co., Ltd. on March 31, 2026, covering a pyrimido pyrimidinone compound that inhibits PD-L1 expression for cancer treatment. The patent includes 9 claims and names 8 inventors including Young Jun Park and Sung Jun Park.

Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection

USPTO granted Patent US12590099B2 to Merck Sharp & Dohme LLC covering HDAC (histone deacetylase) inhibitors useful for treating or preventing HIV infection. The patent protects compounds of Formula I, pharmaceutical compositions thereof, and methods of treatment. Four claims were granted. The patent application was filed on November 4, 2019.

Spiroindoline pyrrolopyrrole triones NRF2-β-TrCP inhibitors for fatty liver treatment

USPTO granted Patent US12590100B2 to researchers from Universidad Autonoma de Madrid and CSIC for spiroindoline pyrrolopyrrole trione compounds that inhibit the NRF2-β-TrCP interaction for treating fatty liver disease. The patent covers 3 claims and relates to therapeutic applications for chronic inflammation and oxidative stress-related liver conditions.

Substituted Entecavir Monophosphate Alaninamide Phenolic Esters for Hepatitis B

The USPTO granted Patent No. US12590097B2 to Beijing Junke Huayuan Med Tech Co., Ltd. on March 31, 2026, covering entecavir monophosphate alaninamide phenolic ester derivatives for hepatitis B treatment. The patent grants exclusive rights to the pharmaceutical compound for resisting hepatitis B virus. This is a routine patent grant notification.

Bristol-Myers Squibb pyrrolo TLR9 inhibitors for fibrosis, 31st Mar

Bristol-Myers Squibb pyrrolo TLR9 inhibitors for fibrosis, 31st Mar

Antiviral agents and uses thereof

The USPTO granted Patent US12590092B2 to Griffith University for antiviral compounds of Formula (I) and pharmaceutical compositions for treating viral infections. The patent, with 21 allowed claims, names Mark Von Itzstein, Ibrahim El-Deeb, Patrice Guillon, and Larissa Heilig as inventors. Filing date was January 28, 2022.

Indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound and use thereof

USPTO granted patent US12590093B2 to the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, covering an indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound for treating cardiovascular and cerebrovascular diseases. The patent lists 13 inventors and contains 4 claims, with applications including increasing expression of AMPK, ABCA1, and SR-BI, and inhibiting NLRP3, IL-1β, NF-κB, and MAPKs.

Cardiac pulse wave retrieval from an electrical signal

USPTO granted Patent US12588824B2 to Onera Technologies B.V. for a method and system of determining cardiac pulse wave signals by processing ECG and electrical signals. The patent includes 20 claims and names inventors Jantina Catharina de Vries and Hartmut Schneider.

Photoplethysmogram Sensor Arrangement Patent

The USPTO granted Patent US12588826B2 to Polar Electro Oy for a photoplethysmogram sensor arrangement. The invention features a light emitter and photo detector in a diagonal orientation with an opaque mask covering part of the detector. The patent contains 12 claims and covers medical sensing technology used in heart rate monitoring devices.

Determining different sleep stages in a wearable medical device patient

USPTO granted patent US12588827B2 to ZOLL Medical Corporation for a patient monitoring device that uses ECG and motion sensors to determine sleep stages and adjust cardiac arrhythmia detection parameters accordingly. The device differentiates between immobilized and non-immobilized sleep states to optimize monitoring modes. The patent covers 16 claims filed under Application No. 17907650.

Body temperature estimation, single sensor, Korea Electronics Technology Institute

Body temperature estimation, single sensor, Korea Electronics Technology Institute

Atlasense Biomed remote physiological monitor patent granted

USPTO granted patent US12588822B2 to Atlasense Biomed Ltd. for a remote physiological monitor system featuring wireless sensors, fall detection algorithms, and alert capabilities. The patent includes 32 claims covering a micromonitor with non-optical pulse wave or ECG sensors and condition monitoring/prediction functionality. Filed August 2, 2021 as Application No. 17392128.

Marker Localization Patent Granted to Cianna Medical

USPTO granted Patent US12588829B2 to Cianna Medical, Inc. for apparatus, systems, and methods used to localize markers or tissue structures within a patient's body, such as for breast lesion localization. The patent (18 claims) covers implantable markers and electromagnetic signal probes for detecting and removing tissue specimens including lesions.

Machine Learning Blood Pressure Monitoring Using Digital Twin Technology

The USPTO granted Twin Health, Inc. Patent US12588823B2 for a machine learning-based blood pressure monitoring system using digital twin technology. The platform generates short-term and long-term blood pressure predictions based on patient-reported nutrition data, sensor readings, and lab test results. The system updates a digital twin of the patient's metabolic profile to enable continuous health monitoring. The patent includes 17 claims and was applied for on April 28, 2021.

Methods and Systems for Diagnosing and Treating Fibromyalgia

The USPTO granted Patent US12588828B2 to inventor Robert S. Katz, covering methods and systems for diagnosing and treating fibromyalgia using pressure measurements from saline injection into muscle locations. The patent protects a device comprising a needle, saline-filled syringe, connecting tube, and pressure sensor. The patent contains 12 claims.

Fused imidazole derivatives as GLP-1 receptor agonists for diabetes treatment

USPTO granted Patent US12590081B2 to Jiangsu Hengrui Pharmaceuticals Co., Ltd. for fused imidazole derivatives as GLP-1 receptor agonists for diabetes treatment. The patent covers 21 claims for compounds, preparation methods, and pharmaceutical compositions containing the derivatives.

Foghorn Therapeutics Patent for Heterocyclic Compounds Treating BAF Disorders

The USPTO granted patent US12590079B2 to Foghorn Therapeutics Inc. on March 31, 2026, covering heterocyclic compounds useful for treating BAF complex-related disorders. The patent names inventors Sabine K. Ruppel, Zhaoxia Yang, and Jason T. Lowe, with claims encompassing 20 compound variations classified under CPC codes C07D 401/14, C07D 471/04, C07D 471/10, and C07D 487/04.

Heterocyclic compound for organic electroluminescent elements

USPTO granted Patent US12590076B2 to Idemitsu Kosan Co., Ltd. for a heterocyclic compound represented by formula (1) used in organic electroluminescent elements. The patent, filed on May 10, 2019 (Application No. 17053630), contains 26 claims and covers compounds classified under CPC codes including C07D 307/91 and H01L 51/0052.

Implant delivery device

USPTO granted patent US12588988B2 to 4C Medical Technologies, Inc. covering an implant delivery device with a constrained/relaxed configuration system. The patent includes a strut with hub-captured end, swivel body, pusher catheter, gauge handle with force measurement, and bushing for guided implant delivery. This represents routine issuance of intellectual property rights for medical device technology.

Devices, systems and methods for repairing lumenal systems

USPTO granted Patent US12588994B2 to Transmural Systems LLC for a tether and prosthesis delivery catheter system designed for repairing lumenal systems, including valve prostheses. The patent contains 12 claims and covers CPC classifications A61F 2/24 (heart valve prostheses) and A61B 17/04 (surgical fasteners).

Interventional Device Delivery Device Patent - Venus MedTech

The USPTO granted patent US12588992B2 to Venus MedTech (Hangzhou), Inc. for an easy-to-control interventional instrument delivery device. The device comprises a core tube with guiding and fixing heads, a slidable outer sheathing tube, and a floating limiting strip designed to prevent valve stent detachment during release and reduce friction during procedures.

Edwards Lifesciences Prosthetic Valve Delivery Patent Granted

The USPTO granted patent US12588991B2 to Edwards Lifesciences Corporation covering a prosthetic valve delivery apparatus with a dual-configuration indicator arm that signals when valve expansion reaches a predetermined diameter. The patent includes 18 claims and names inventors Elazar Levi Schwarcz, Oren Cohen, and Ofir Witzman.

Delivery apparatus for a prosthetic heart valve

USPTO granted patent US12588990B2 to Edwards Lifesciences Corporation on March 31, 2026, covering a delivery apparatus handle for prosthetic heart valves with an actuation knob featuring a toggle mechanism. The toggle allows operators to switch between moving multiple elements (for frame expansion/collapsing) and moving a single element (for locking/releasing the frame). The patent contains 18 claims.

Implant delivery patent by 4C Medical, US12588989B2, granted Mar 31

Implant delivery patent by 4C Medical, US12588989B2, granted Mar 31

Heart valve sealing devices and delivery devices therefor

USPTO granted patent US12588997B2 to Edwards Lifesciences Corporation for a heart valve sealing device with 9 claims. The patent covers valve repair devices with a main shaft and moveable paddles configured between open and closed positions. The filing date was April 14, 2022.

Cardiac valve repair devices and associated systems and methods

The USPTO granted Medtronic Patent US12588996B2 for cardiac valve repair devices and associated systems and methods. The patent covers coaptation members configured to be positioned between native cardiac valve leaflets and fixation mechanisms for securing the device in position. Inventors include Katherine Miyashiro, Hanson S. Gifford III, and James I. Fann among 16 total inventors.

Transvalvular Intraanular Band and Chordae Cutting for Mitral Valve Treatment

The USPTO granted Patent US12588995B2 to Heart Repair Technologies, Inc. for a transvalvular intraannular band designed to treat mitral valve prolapse and mitral regurgitation. The patent (20 claims) covers a band implanted in the mitral annulus that extends across the coaptive edge of mitral valve leaflets to inhibit prolapse, combined with severing of at least one marginal chordae to permit leaflet closure against the band.

Prosthetic heart valve delivery device and methods using supra-annular support

USPTO granted Patent US12588993B2 to VDyne, Inc. for a prosthetic heart valve delivery system using supra-annular support. The invention includes a delivery sheath with a control device that advances and deploys prosthetic valves in a compressed-to-expanded configuration. The 30-claim patent covers methods for stabilizing prosthetic valves relative to native heart valve anatomy during deployment.

Ophthalmic apparatus, method of controlling same, and recording medium

USPTO granted patent US12588812B2 to TOPCON CORPORATION on March 31, 2026, for an ophthalmic apparatus with an illumination optical system, optical scanner, and imaging optical system for fundus examination. The patent (15 claims) covers technology for slit-shaped illumination light scanning and synchronized image capture controlled by scanner position signals.

Optical system and operating method thereof

The USPTO granted Crystalvue Medical Corporation Patent No. US12588813B2 for an optical system used in fundus examination and eye therapy. The patent covers a light source device, gaze module, and fundus detection device integrated for eye examination and treatment. The patent includes 20 claims and names William Wang, Hsuan-Hao Chao, Sung-Yang Wei, and Chung-Cheng Chou as inventors.

Vision screening device including oversampling sensor

USPTO granted Patent No. US12588814B2 to Welch Allyn, Inc. for a vision screening device featuring an oversampling sensor that allows operation at various distances from patients. The patent (20 claims) covers methods and systems for capturing oversampled images, detecting faces and eyes, tracking eye movements, and providing guidance for optimal positioning to generate stabilized eye images meeting vision screening criteria.

Bionime Physiological Signal Monitoring Device

The USPTO granted patent US12588815B2 to Bionime Corporation for a physiological signal monitoring device. The device comprises a base, biosensor with sensing member for subcutaneous analyte measurement, transmitter, and sealing unit to protect against liquid ingress. The patent, with 14 claims, names Chun-Mu Huang, Chieh-Hsing Chen, and Chen-Hao Lee as inventors.

Telemonitoring Respiration System Patent Granted

The USPTO granted Patent No. US12588816B2 to Loewenstein Medical Technology S.A. for a telemonitoring respiration system combining a respirator with sensors for pressure/flow/volume measurement, user health input capabilities, and automated data transmission to remote monitoring units. The patent contains 9 claims and was applied for on September 11, 2019.

MRI Diagnostic Scan Parameters from Calibration Images

The USPTO granted patent US12588817B2 to GE Precision Healthcare LLC for methods and systems that determine MRI diagnostic scan parameters directly from calibration images, bypassing the need for separate localizer images. The patent covers a trained deep neural network that maps calibration images to landmark maps to generate high-resolution diagnostic images more efficiently.

Tufts Medical eye inflammation patent US12588809B2, 31st Mar

Tufts Medical eye inflammation patent US12588809B2, 31st Mar

Eye Length Measurement Arrangement and Method

USPTO granted Patent US12588810B2 to Heidelberg Engineering GmbH for an arrangement and method of measuring eye length using a light source that emits a central light ray and radially offset peripheral light rays to the cornea, with a control unit converting reflected light into measurement signals. The patent has 8 claims and covers ophthalmic measurement technology applicable to diagnostic imaging devices.

Modular platform for ocular evaluations

USPTO granted Patent US12588811B2 to Icahn School of Medicine at Mount Sinai for a modular screening platform enabling comprehensive ocular evaluations. The platform features a head-mounted harness with interchangeable electronic modules, CPU/GPU processing capabilities, multiple display outputs, and input devices for both operators and patients. The patent contains 27 claims covering the modular design and separable interchangeable components.

GPR139 Antagonist Patent for Depression and Neurological Disorders

USPTO granted Takeda Pharmaceutical Company Limited Patent US12590086B2 for GPR139 antagonist compounds (3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives) used in methods of treating depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and ADHD. The patent contains 27 claims and includes tablet formulations.

Fused tricyclic drug patent granted, Mar 31

Fused tricyclic drug patent granted, Mar 31

SPNS2 inhibitors patent granted to University of Virginia

USPTO granted patent US12590083B2 to the University of Virginia Patent Foundation covering SPNS2 (spinster homolog 2) inhibitor compounds and their pharmaceutical compositions for therapeutic use. The patent, with 2 claims, protects Formula I compounds and methods of treatment using these inhibitors.

Oxadiazole HDAC6 inhibitors and uses thereof

The USPTO granted Patent US12590084B2 to Eikonizo Therapeutics, Inc. covering oxadiazole compounds that selectively inhibit HDAC6, a protein linked to cancer and neurological disorders including Alzheimer's disease. The patent includes 20 claims and covers pharmaceutical compositions and methods of treating HDAC6-related diseases. Inventors are Florence Fevrier Wagner and Thomas Edward Richardson.

JAK Inhibitor Compound and Pharmaceutical Composition Patent

USPTO granted Patent US12590088B2 to Korea Pharma Co., Ltd. on March 31, 2026, covering a JAK inhibitor compound and pharmaceutical composition. The patent claims 4 items related to compounds of Formula I and their use in treating inflammatory, autoimmune, myeloproliferative diseases, and human cancers by regulating JAK kinase signal transduction.

Gilead Sciences patent for toll-like receptor modulator compounds

USPTO granted Patent US12590089B2 to Gilead Sciences covering methods for preparing toll-like receptor modulator compounds. The patent, naming 12 inventors including Andrea Ambrosi and Pavel R. Badalov, contains 7 claims relating to (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol or salts thereof. Application No. 17673141 was filed February 16, 2022.

Pyrimidine-Nitrogen Bicyclic IRAK-4 Inhibitor Compound Patent

USPTO granted patent US12590090B2 to Asahi Kasei Pharma Corporation covering pyrimidine-and nitrogen-containing bicyclic compounds with IRAK-4 inhibitory activity. The patent, with 35 claims filed on September 30, 2020, protects compounds useful for prophylactic and therapeutic treatment of diseases relating to IRAK-4 inhibition.

Bipartite molecules treating neurodegenerative diseases

USPTO granted Patent US12590130B2 to Academia Sinica for bipartite molecules comprising a peptide affinity moiety and charged moieties for treating neurodegenerative diseases associated with abnormal protein aggregates. The patent contains 6 claims and was granted March 31, 2026, with original filing date November 27, 2020. No compliance deadlines are associated with this patent grant.

UFABC patents KLK7 antibodies, skin desquamation, 31st Mar

UFABC patents KLK7 antibodies, skin desquamation, 31st Mar

Materials and Methods for Isolating Self-Antigen Polypeptides

The USPTO issued Patent Grant US12590120B2 to Impact Proteomics covering materials and methods for isolating self-antigen polypeptides. The patent names inventors Jonathan Minden and Dana Ascherman and contains 19 claims. This grant confers exclusive rights to the patented technology for the patent term.

NRP-1 binding inhibitory peptides and uses thereof

USPTO granted patent US12590122B2 to INSERM for NRP-1 binding inhibitory peptides with anti-angiogenic properties for cancer treatment. The patent covers novel peptide-like compounds with nanomolar affinity for NRP-1 that inhibit VEGF-A165/NRP-1 interaction, representing an improvement over the prior A7R heptapeptide. Application 17618233 (filed June 10, 2020) contains 15 claims.

Protease Inhibitor Compounds for Treating Cancer, Viral Infections, and Allergic Conditions

USPTO granted patent US12590123B2 to Washington University covering protease inhibitor compounds useful for treating coronaviruses, cancer, and allergic conditions. The patent discloses compounds inhibiting S1 serine proteases (HGFA, matriptase, hepsin, KLK5, TMPRSS2) and cysteine proteases with 10 claims. Filing date was June 25, 2020, with application number 17620169.

Peptide with Neutralizing Activity Against SARS-CoV-2

The USPTO granted patent US12590124B2 to CAREGEN CO, LTD. for a peptide composition that specifically recognizes and neutralizes SARS-CoV-2. The patent covers both therapeutic applications for preventing or treating COVID-19 infection and diagnostic applications for detecting the virus. The patent contains 13 claims and lists 6 inventors.

Split PYP Complementation System for Detecting Protein Interactions

USPTO granted patent US12590127B2 to PARIS SCIENCES ET LETTRES for a split photoactive yellow protein (PYP) complementation system for detecting protein interactions. The patent covers two PYP fragments with at least 70% sequence identity to SEQ ID NO:23 and SEQ ID NO:34, used with fluorogenic HBR analogs for protein interaction detection. The grant includes 19 allowed claims.

Acetohydroxy acid synthase variant and microorganism including the same

USPTO granted patent US12590128B2 to CJ CheilJedang Corporation on March 31, 2026, for an acetohydroxy acid synthase variant, polynucleotides encoding it, microorganisms containing it, and a method for producing L-isoleucine using the microorganism. The patent has 20 claims.

Phenylethynyl-thiophene compounds for treating degenerative disorders

The USPTO granted patent US12589090B2 to Aquilus Pharmaceuticals, Inc. covering phenylethynyl-thiophene compounds that inhibit caspase 3 for treating degenerative disorders including ALS, Huntington's disease, epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's disease. The patent claims 2 compounds and methods for their use.

Elafibranor treats Primary Biliary Cholangitis, Genfit patent

Elafibranor treats Primary Biliary Cholangitis, Genfit patent

Treatment of cachexia using fibroblast cells and products thereof

USPTO granted patent US12589119B2 to Fibrobiologics, Inc. covering methods and compositions for treating cachexia using immune-modulating fibroblasts. Inventors Pete O'Heeron and Thomas Ichim disclosed compositions including immune-modulating fibroblasts for treatment, amelioration, or prevention of cachexia or inflammation related to cachexia. The patent contains 12 claims.

Anaerostipes caccae Compositions for Treating Allergic and Autoimmune Diseases

USPTO granted Patent US12589122B2 to the University of Chicago on March 31, 2026, covering compositions and methods for treating infectious, autoimmune, allergic diseases, and food allergies using the bacterium Anaerostipes caccae. The patent includes methods for reducing allergic responses and preventing anaphylactic responses, with claims extending to compositions comprising the bacterium with prebiotics.

Bacteriophages for treatment of tuberculosis

USPTO granted Patent US12589127B2 to the University of Pittsburgh for pharmaceutical compositions comprising five or more bacteriophages designed to treat Mycobacterium tuberculosis infections. The patent covers methods of treating drug-resistant TB and preventing activation of latent TB disease, with 20 claims covering the phage combinations and treatment methods.

Aloe vera polysaccharide antimicrobial composition patent grant

USPTO granted Patent US12589130B2 to 2QR RESEARCH B.V. on March 31, 2026. The patent covers Aloe vera polysaccharide compositions with antimicrobial aggregating activity, having molecular weight of 30-100 kDa and comprising 80-100% w/w mannose. Inventors are Floris Koumans and Paul Kwakman. The patent has 14 claims.

Viral vectors with RDH12 coding regions for treating retinal dystrophies

The USPTO granted Patent US12589136B2 to The Regents of the University of Michigan covering viral vectors comprising RDH12 coding regions and methods of using such vectors to treat retinal dystrophies, including Leber Congenital Amaurosis. The patent, with 12 claims, names Debra A. Thompson, Robin R. Ali, and Alexander J. Smith as inventors. The patent covers nucleic acids encoding human RDH12 protein and their use in gene therapy applications for ophthalmological conditions caused by loss-of-function mutations.

DNA Vaccine for Treating and Preventing Type 1 Diabetes

USPTO granted Patent US12589141B2 to The Fifth Medical Center of Chinese PLA General Hospital for a DNA vaccine using a B7-2-PE40 exotoxin fusion gene to treat Type 1 Diabetes. The patent, with 10 claims, covers reduction of blood glucose, restoration of insulin secretion, and reduction of islet cell autoantibody (ICA) and glutamate decarboxylase autoantibody (GAD) levels. The application was filed on March 2, 2020.

Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof

The USPTO granted Patent US12589140B2 to The Brigham and Women's Hospital, Inc. covering methods for generating immune responses to cancer or infection by promoting differentiation of neutrophils into dendritic cells using GMCSF combined with immune complexes or anti-FcγRIIIB antibodies. The patent contains 14 claims and lists Tanya Mayadas, Vijaya Mysore, Xavier Cullere, and Jon C. Aster as inventors.

NOVOSEVEN Registered Trademark for Factor VIIa Hemophilia Treatment

USPTO has registered the trademark NOVOSEVEN (Registration No. TM74546941) for a Factor VIIa pharmaceutical preparation used in hemophilia treatment. The trademark was registered on March 30, 2026, with an original filing date of July 7, 1994. This is an informational trademark registration notice with no new compliance requirements.

Compliant Biological Scaffold with Biaxial Expansion

USPTO granted patent US12588985B2 to inventor Brent Schultz for a compliant biological scaffold incorporating elongated apertures arranged in geometric patterns that enable biaxial expansion or contraction. The scaffold may be formed in biological material in vivo or ex vivo and has applications in prosthetics and medical implants. The patent contains 25 claims and is classified under CPC codes A61F 2/86, A61F 2/90, and A61F 2/0063.

Thumb brace design patent

USPTO issued Design Patent USD1121164S1 to Dongguan Feibu Industrial Co., Ltd. for a thumb brace. The patent, with a single claim, was granted March 31, 2026, based on application filed January 14, 2025.

Knee brace design patent

The USPTO granted Design Patent USD1121161S1 to Shock Doctor, Inc. for an ornamental knee brace design. The patent was issued on March 31, 2026, based on application No. 29944597 filed on May 29, 2024. The patent contains one design claim covering the visual appearance of the knee brace.

Penile sleeve implant patent granted to Loria Cosmetic Urology

USPTO granted Design Patent USD1121151S1 to Loria Cosmetic Urology LLC for a penile sleeve implant. The patent was issued on March 31, 2026, with Victor Loria listed as the sole inventor and one design claim. CPC classifications indicate the device falls under male reproductive system medical devices (A61F 2/26, A61F 5/41).

Knee Brace Design

The USPTO granted design patent USD1121163S1 for a knee brace to Guangdong Transcontinental Technology Co., Ltd. The patent covers the ornamental design of the knee brace with one claim. Filing date was December 5, 2024, and the grant date is March 31, 2026.

Low profile transcatheter heart valve

USPTO issued patent grant US12588987B2 to Edwards Lifesciences Corporation on March 31, 2026, covering a low profile transcatheter heart valve prosthetic. The invention includes a radially collapsible and expandable annular frame with three commissure attachment posts, four rows of circumferential struts, and a three-leaflet structure.

Peptide-derived KDM5C targeting cancer therapeutics patent grant

USPTO granted Patent US12589160B2 to NUVOBIO CORPORATION covering peptide-derived therapeutics targeting KDM5C for cancer treatment. The patent, filed on March 12, 2020, contains 6 claims and names inventors Kyle Kevin Biggar, Hemanta Adhikary, and Matthew Jacob Hoekstra. This grant establishes exclusive intellectual property rights for the assignee in the United States.

Multivalent HVT vector vaccine for poultry

USPTO granted Patent US12589147B2 to Intervet Inc. for a recombinant herpesvirus of turkeys (rHVT) vector vaccine expressing antigens from IBDV, NDV, and AIV. The patent covers 20 claims and can be used to vaccinate poultry against four diseases: MDV, IBDV, NDV, and AIV simultaneously.

HLA tumor antigen peptides of class I and II for treating mammary/breast carcinomas

The USPTO granted Patent US12589142B2 to PMCR GmbH covering pharmaceutical compositions comprising HLA-A tumor antigen peptides (4-8 peptides for MHC class I and 2+ for MHC class II) for treating breast carcinomas. The patent includes 4 claims and covers methods for preparing the composition and determining HLA peptides.

Hangzhou Innogate Pharma, kinase inhibitor patent, CDK TRK

Hangzhou Innogate Pharma, kinase inhibitor patent, CDK TRK

Plasma kallikrein inhibitor patent for ocular disorders

The USPTO granted BioCryst Pharmaceuticals patent US12589093B2 covering plasma kallikrein inhibitor compositions for treating ocular disorders. The patent claims avoralstat-based drug compositions delivered via suprachoroidal space injection. The patent contains 16 claims and names inventors Yarlagadda Babu, Viral Kansara, and Rick McElheny.

Regeneron cyclodextrin protein drug conjugates

USPTO granted patent US12589101B2 to Regeneron Pharmaceuticals for cyclodextrin protein drug conjugates used in treating proliferative diseases. The patent contains 41 claims and covers compounds, compositions, and conjugates with cyclodextrin-based linker-payloads. Inventors: Amy Han and William Olson. Filing date: June 10, 2022.

ALPHA-1062 Pharmaceutical Composition for Treating Traumatic Brain Injury

USPTO granted Patent US12589099B2 to Alpha Cognition Inc. for a pharmaceutical composition containing ALPHA-1062 (or salt thereof) for treating confirmed or suspected traumatic brain injury (TBI). The patent includes 27 claims covering transmucosal/intranasal administration methods and a multi-use dispenser configuration. The composition may be self-preserving and anti-microbial.

Injectable sustained-release formulations for treatment of joint pain and inflammation

USPTO granted patent US12589102B2 to FORDOZ Pharma Corp. covering injectable drug-loaded microspheres combining steroidal and non-steroidal anti-inflammatory drugs for sustained release. The patent also protects methods of making the microspheres and using them to treat rheumatoid arthritis and osteoarthritis. The patent contains 9 claims and names inventors Sydney Ugwu, James He, and Zengli Fu.

Ruxolitinib formulation for reduction of itch in atopic dermatitis

USPTO granted Patent US12589096B2 to Incyte Corporation on March 31, 2026. The patent covers a topical 0.75% or 1.5% ruxolitinib cream formulation administered two times per day for reducing itch in patients with atopic dermatitis. The patent includes 20 claims and names Michael Kuligowski, Kang Sun, Michael Howell, May Grace E. Venturanza, and Jim Lee as inventors.

C2-C7 alkyl boronic acids as antimicrobial antiviral therapeutic compounds

USPTO granted patent US12589103B2 to Cornell University covering methods for treating bacteria and viruses using C2-C7 alkyl boronic acids to reduce growth and virulence. The patent, filed October 7, 2020, names inventors Kenneth W. Simpson, Shiying Zhang, and Michael Fischbach and contains 28 claims.

Glucocorticoid receptor modulator relacorilant with paclitaxel patent granted

USPTO granted patent US12589094B2 to Corcept Therapeutics Incorporated on March 31, 2026, covering methods of co-administering glucocorticoid receptor modulator relacorilant with paclitaxel by reducing paclitaxel dose to approximately half when used together. The patent addresses drug-drug interaction management, noting that despite in vitro predictions of 5-fold increased paclitaxel exposure, in vivo co-administration showed only 80% increase, enabling a safer combination therapy for treating cancers such as ovarian and pancreatic.

Crystalline Salts of Plasma Kallikrein Inhibitor Patent

USPTO granted patent US12590069B2 to BioCryst Pharmaceuticals, Inc. covering crystalline salts of a plasma kallikrein inhibitor (Compound I), methods of preparation, pharmaceutical preparations, and methods of treatment. The patent (30 claims) names inventors Yahya El-Kattan and Yarlagadda S. Babu, with an August 28, 2025 filing date. This is a routine patent grant establishing intellectual property protection with no new regulatory compliance obligations.

Thyromimetics Patent - Autobahn Therapeutics

USPTO granted patent US12590072B2 to Autobahn Therapeutics, Inc. covering thyromimetic compounds for treating neurodegenerative disorders and fibrotic diseases. The patent (20 claims) names inventors Thomas von Geldern and Bradley Backes, with original filing date June 17, 2021. This is a routine patent grant notice with no compliance obligations.

Process for preparation of macrocyclic chelant and metal complexes

USPTO granted patent US12590073B2 to Biophore India Pharmaceuticals Pvt. Ltd. for an improved process preparing macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid and its gadolinium/calcium metal complexes with purity exceeding 99.0% by HPLC. The patent names inventors Manik Reddy Pullagurla and Jagadeesh Babu Rangisetty, with 9 claims granted.

Method of fixating carbon dioxide to substituted oxazolidinones using MOF technology

USPTO granted patent US12590074B2 to King Fahd University of Petroleum and Minerals on March 31, 2026. The patent covers a method of fixating carbon dioxide (CO2) to form substituted oxazolidinones using a MIL-68(In)-X metal-organic framework (MOF) catalyst, reacting CO2 with epoxides and aromatic amines. The patent contains 20 claims and application number 18329092.

Hydrazone derivative with aryl-substituted terminal amine group and use thereof

USPTO granted Patent No. US12590071B2 to Korea Institute of Science and Technology on March 31, 2026, covering hydrazone derivatives where the terminal amine group is substituted with aryl or heteroaryl groups. The patent includes 14 claims relating to compounds represented by Formulas 3 and 4, and methods of making these compounds. The patent relates to heterocyclic organic chemistry with potential pharmaceutical applications.

Adamantane derivatives as inhibitors of focal adhesion kinase

USPTO granted patent US12590070B2 to Samjin Pharmaceutical Co., Ltd. on March 31, 2026, covering novel adamantane derivatives as inhibitors of focal adhesion kinase (FAK) for pharmaceutical use. The patent includes 17 allowed claims and covers compounds, salts, stereoisomers, and pharmaceutical compositions. The invention is classified under CPC codes including C07D 239/48, C07D 401/12, and A61P 35/00 (antineoplastic agents).

Crystalline salts of plasma kallikrein inhibitor patent grant

USPTO granted BioCryst Pharmaceuticals, Inc. Patent US12590068B2 covering crystalline salts of a plasma kallikrein inhibitor (Compound I), methods of preparation, and related pharmaceutical preparations. Inventors: Yahya El-Kattan and Yarlagadda S. Babu. The patent contains 30 claims and 3 CPC classifications (C07D 231/14, A61K 9/0029, C07B 2200/13).

CIRA HEALTH SOLUTIONS Trademark Application - Medical Services

The USPTO published trademark application TM87528125 for CIRA HEALTH SOLUTIONS covering medical services in Class 044. The application includes web portal software for managing medical documents, invoices, and scheduling; independent medical examinations; health assessments; medical file reviews; and expert witness services for legal matters in the medical field. This is an Intent to Use application filed on July 14, 2017.

COVID-19 Vaccine Antigen Composition Data Request for May 2026

WHO's Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) has issued updated guidance requesting vaccine manufacturers submit immunological, virological, and vaccine effectiveness data ahead of the May 2026 decision-making meeting. The statement updates previous September 2025 guidance and specifies key antisera and antigens of interest including JN.1, KP.2, XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2 variants. Manufacturers should submit both pre- and post-vaccination antisera analysis for neutralization testing.

Diaminoguanidine derivative treats bacterial infections in farmed animals

USPTO granted patent US12589085B2 to Guangzhou Insighter Biotechnology Co., Ltd. for a diaminoguanidine derivative compound and feed composition for veterinary use in preventing and treating bacterial infections in farmed animals. The patent covers the compound with R1 as C1-C20 alkyl, applications including reproductive system and skin infections, and includes 11 claims.

Production of antibodies by modification of autonomous heavy chain variable domain via gene conversion

USPTO granted patent US12588664B2 to Crystal Bioscience Inc. on March 31, 2026. The patent covers transgenic animals engineered with B cells that use gene conversion for antibody diversification, involving functional immunoglobulin heavy chain genes and operably linked pseudogenes that donate sequence to enable diversification.

Otoferlin Dual Vector Systems for Treating Sensorineural Hearing Loss

The USPTO granted Regeneron Pharmaceuticals Patent US12589168B2 for compositions and methods treating sensorineural hearing loss using otoferlin (OTOF) dual vector gene therapy systems. The patent covers a two-vector approach delivering N-terminal and C-terminal portions of OTOF isoform 5 to restore gene function in patients with OTOF mutations. Application No. 17733744 was filed April 29, 2022.

Root-knot Nematode Resistance Gene Patent Grant

USPTO granted patent US12588644B2 to Rijk Zwaan Zaadteelt En Zaadhandel B.V. covering a nucleic acid encoding the MeR1 protein that confers resistance to root-knot nematode in Solanaceae plants. The patent includes 18 claims covering the gene sequences, amino acid sequences, and methods of using the resistance gene in plant breeding. The inventors are Raoul Jacobus Johannes Maria Frijters, Jonathan Kalisvaart, and Adriaan Verhage.

CD80 Extracellular Domain Fc Fusion Proteins for Treating PD-L1 Negative Tumors

The USPTO granted Patent US12589132B2 to Five Prime Therapeutics, Inc. covering fusion proteins combining the CD80 extracellular domain with the Fc domain of IgG1 for treating PD-L1 negative tumors. The patent includes 22 claims and names Susannah D. Barbee, Thomas Brennan, and Barbara Sennino as inventors. This grant establishes exclusive rights for the assignee in this therapeutic application.

177Lu peptide targets uPAR receptor for colorectal cancer treatment

USPTO granted patent US12589171B2 to TRT INNOVATIONS APS covering a 177-Lu labeled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) for treatment of cancers with high uPAR expression, particularly colorectal cancer. The patent includes 9 claims and lists inventors Andreas Kjaer, Morten Persson, and Michael Ploug.

Method for producing modified pea protein

USPTO granted patent US12588686B2 to Ajinomoto Co., Inc. covering methods for producing modified pea protein with improved solubility. The method involves treating pea ground product with acid and conducting enzyme reactions using protein deamidase. The patent contains 4 claims and names three inventors.

Cerebrolysin patent for CADASIL treatment

USPTO granted patent US12589118B2 to Ever Neuro Pharma GmbH for a method of using cerebrolysin to reduce mortality in patients with CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). The patent includes 15 claims and was filed on August 28, 2018.

Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof

USPTO granted Patent US12590066B2 to Korea Institute of Science and Technology for novel fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds. The patent includes 20 claims and names inventors Ae Nim Pae, Yun Kyung Kim, Sang Min Lim, Sungsu Lim, Haeun Lee, Woo Seung Son, and Hye Yeon Lee. The compounds have potential pharmaceutical applications.

Process for the production of levetiracetam

USPTO granted Patent US12590059B2 to Suzhou BrightHope Pharmatech Co., Ltd. for a process to produce levetiracetam via crystallization in aqueous solution, resulting in a product containing no residual organic solvent. The patent lists 4 inventors (Songzhou Hu, Lijun Deng, Wen Yu, Zhen Song) and contains 13 claims under classification C07D 207/27.

Levorphanol prodrugs and processes for making and using them

The USPTO granted Patent US12590065B2 to Zevra Therapeutics, Inc. covering novel levorphanol prodrug compositions formed by chemically conjugating oxoacids, polyethylene glycols, or vitamin compounds to levorphanol. The patent includes claims to the compositions and methods of making and using them.

Information Collection Request Comment Notice

CMS published a Federal Register notice announcing a 60-day public comment period on a proposed information collection (CMS-10752) under the Paperwork Reduction Act. The collection relates to Medicare and Medicaid program information gathering. Comments must be received by June 1, 2026.

Digital Health Technologies in Clinical Investigations - Request for Comments

FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have issued a Request for Information on the use of Digital Health Technologies (DHTs) in clinical investigations for drugs and biological products. The agency seeks stakeholder input on opportunities, challenges, and best practices before potential future regulatory activities. Comments are due June 1, 2026.

FDA Decision Denying Hearing Request on TRADIPITANT Approval Refusal

The FDA issued a decision denying Vanda Pharmaceuticals' request for a hearing regarding CDER's proposal to refuse approval of NDA 218489 for TRADIPITANT capsules (85 mg) for the treatment of gastroparesis symptoms. The decision upholds the complete response letter issued September 18, 2024, and the Notice of Opportunity for Hearing published January 16, 2025 (90 FR 4748).

Proposed LIHEAP FY25 Funds Reallotment to States Territories Tribes

The ACF Office of Community Services announces a preliminary determination that $2,697,089 in FY25 LIHEAP funds and $484,019.07 in IIJA funds (total $3,181,108.07) are available for reallotment to states, territories, tribes, and tribal organizations that received FY26 direct awards. This notice opens a 30-day comment period ending April 30, 2026.

TANF Financial Report Form ACF-196T OMB Review

The Administration for Children and Families (ACF) requests a 3-year extension of the TANF Financial Report Form ACF-196T for tribal agencies administering TANF programs. ACF proposes significant updates to streamline and improve instructions, reducing estimated review time by 33 percent (from 1.5 to 1 hour per response). Annual burden decreases from 306 to 200 hours. Public comments are due April 30, 2026.

Phototherapeutic LED apparatus trademark for medical skin treatments

The USPTO received trademark application TM99731327 for ASCENT PRAXXIS covering Class 10 medical device goods including phototherapeutic LED apparatus, light therapy devices for skin treatments, and related medical-aesthetic equipment. The application was filed on an Intent-to-Use basis on March 29, 2026.

NIH Center for Scientific Review closed meetings, 31st Mar

NIH Center for Scientific Review closed meetings, 31st Mar

Notice of Closed Meetings for Grant Application Reviews

The NIH Center for Scientific Review published a Federal Register notice announcing five closed meetings scheduled for April 20-24, 2026, pursuant to section 1009 of the Federal Advisory Committee Act. The meetings will review grant applications including the MIST (U01) program, Health Services Career Development Awards, and various biomedical research topics. Meetings are closed under Government in the Sunshine Act exemptions to protect confidential trade secrets and personal privacy.

Medical Expenditure Panel Survey Household Component Comment Request

AHRQ published a 30-day comment request notice for the Medical Expenditure Panel Survey (MEPS) Household Component (OMB No. 0935-0118). The survey collects data on health services usage, costs, and insurance coverage. Comments must be submitted by April 30, 2026.

Agency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Black Lung Clinics Program Performance Measures, OMB No. 0915-0292-Revision

HRSA requests public comment, Black Lung Clinics Program

MODERN ORTHODONTICS Trademark Application

USPTO published trademark application TM99731462 for MODERN ORTHODONTICS on March 30, 2026. The application covers orthodontic services under Class 044. Third parties have until April 29, 2026 to file an opposition with the Trademark Trial and Appeal Board.

Magic Eyes Trademark - Sexual Lubricants and Sex Toys

The USPTO renewed Trademark TM87136624 for "Magic Eyes" covering personal sexual lubricants, love dolls, and sex toys. The registration was renewed on March 29, 2026, extending protection for goods in International Class 005. Original filing date was August 12, 2016.

SALONPAS HOT Trademark Renewal

The USPTO renewed trademark registration TM87144971 for SALONPAS HOT pain relief patches on March 29, 2026. The trademark covers medicated transdermal patches and plasters for relief of muscle and joint aches. This is a routine administrative renewal confirming continued trademark protection.

INJURECOV Trademark Renewal

USPTO renewed trademark TM87144175 for INJURECOV, covering herbal supplements in Class 005 (pharmaceuticals). The trademark was originally filed on August 19, 2016 and has been renewed for another registration period. This is a routine administrative trademark renewal with no new obligations.

Flucelvax Quadrivalent Influenza Vaccine Trademark Renewal

The USPTO renewed trademark registration TM87135582 for "Flucelvax Quadrivalent," an influenza vaccine for human use. The renewal was granted on March 29, 2026, extending the trademark protection for the pharmaceutical product branding originally filed on August 11, 2016.

MEDICHOICE Trademark Registration for Medical Products

USPTO registered trademark TM76352417 for MEDICHOICE covering a broad range of medical and surgical products and supplies. The trademark covers goods including disposable medical apparel, surgical instruments, patient examination equipment, and various medical supplies. The original filing date was December 26, 2001.

ACF Repatriation Program Burden Reduction

The Department of Health and Human Services, Administration for Children and Families (ACF) issued a Notice of Proposed Rulemaking (NPRM) to amend regulations governing the care and treatment of mentally ill U.S. nationals and assistance for U.S. citizens returned from foreign countries. The proposal seeks to rescind duplicative, obsolete, and overly prescriptive regulations in 45 CFR parts 211 and 212. Comments on the proposed rule must be received by April 27, 2026.

Native American Programs Act - Reduction of Unnecessary Regulations

The Administration for Children and Families (ACF) published a Notice of Proposed Rulemaking (RIN0970-AD36) to amend the Native American Programs Act regulations (45 CFR part 1336) by eliminating unnecessary, duplicative, and obsolete regulations. The proposed rescissions would impact States, Territories, and Tribal Lead Agencies that receive funding under the Administration for Native Americans (ANA) grant program. Public comments will be accepted until April 27, 2026.

Rescission of Obsolete State Legalization Impact Assistance Grants Regulations

The Administration for Children and Families issued a direct final rule rescinding 45 CFR part 402, which governed the obsolete State Legalization Impact Assistance Grants (SLIAG) program. The SLIAG program, established under the Immigration Reform and Control Act of 1986, was repealed in 1998 and its regulations are no longer operational. The rule removes this outdated regulatory framework as part of HHS's broader deregulatory initiative.

Health Facility Complaint Portal Launch

The South Carolina Department of Public Health (DPH) launched a new online complaint portal for licensed health care facilities and professionals. The portal streamlines complaint submission for the public and automates facility information lookup to assist DPH staff with triage. Healthcare facilities can also use the portal to report required serious accidents and incidents.

Bio Products Laboratory Rabies Immunoglobulin Batch Recall - Reduced Potency

MHRA issued a Class 2 medicines recall for Bio Products Laboratory Limited's batch JRC24208 of Rabies Human Normal Immunoglobulin 500IU solution for injection due to stability failure causing reduced potency. Approximately 1,414 packs distributed since October 2024 are affected, expiring April 2027. Healthcare professionals must immediately quarantine and return the affected stock. No adverse events have been reported.

Florida AHCA Six-Month Moratorium on DME Medicaid Enrollment

Florida's Agency for Healthcare Administration (AHCA) has implemented a six-month moratorium on new Durable Medical Equipment (DME) provider Medicaid enrollment, effective March 20, 2026. The moratorium applies statewide to all 67 Florida counties and targets new applications only; applications received before the effective date continue processing. Exemptions include pharmacies, hospitals, and entities furnishing DME as a secondary function. This action follows a similar federal CMS moratorium and targets fraud prevention in a state identified as high-risk for DME-related fraud.

CMS ACCESS Model ties digital health payments to clinical outcomes

The Centers for Medicare & Medicaid Services (CMS) announced the Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model, testing Outcome-Aligned Payments where fixed per-beneficiary payments ($90-$420 annually) are contingent on Medicare beneficiaries achieving measurable clinical outcomes. The model covers four Clinical Tracks focused on cardio-kidney-metabolic conditions, musculoskeletal pain, and behavioral health, with applications for the first cohort due April 1, 2026.

Advance Care Planning Fact Sheet

CMS published a fact sheet (MLN909289) explaining the voluntary Advance Care Planning service available under Medicare. The service is a face-to-face encounter where Medicare beneficiaries can discuss their healthcare wishes with providers if they become unable to make medical decisions. The fact sheet serves as educational material for healthcare providers and patients.

CLIA Program Medicare Lab Services Fact Sheet

CMS Medicare Learning Network published an updated fact sheet (MLN006270) explaining the CLIA Program requirements for Medicare-participating laboratories. The document covers enrollment procedures, types of laboratory certificates, and test method categorization.

Fee-for-Service Claims Processing Correction Notice

The Louisiana Department of Health issued a notice regarding a system error by Gainwell Technologies affecting fee-for-service claims processed on November 4 and December 9, 2025. Due to a ClaimsXten editing system failure, certain professional, outpatient hospital, and DME claims were paid without proper NCCI edits. LDH will void and reprocess affected claims beginning March 31, 2026.

Used Oil Transporter Cited for Operating Without a Permit

The Hawai'i Department of Health issued a Notice of Violation and Order (NOVO) against Unitek Solvent Services, Inc. for operating used oil facilities without required permits at four locations across O'ahu, Kaua'i, Maui, and Hawai'i Island. The company was assessed a penalty of $116,250 for nine violations including failure to renew permits, obtain EPA ID numbers, and submit annual used oil reports. Unitek has 20 days to respond to the order.

Moxifloxacin ophthalmic solution recall due to assay out of trend

Health Canada issued a Type II recall for pms-MOXIFLOXACIN HCL 0.5% Ophthalmic Solution (DIN 02432218, Lot 240518) distributed nationally by Pharmascience. The recall was triggered because the assay is out of trend for the affected lot. Healthcare providers and consumers should verify if they have the affected product and consult with healthcare professionals before discontinuing use.